



GB03/002862

#2



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport

South Wales
NP10 8QQ
REC'D 01 AUG 2003

WIPO PCT


**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



P. Mahoney

Signed

Dated 22 July 2003

BEST AVAILABLE COPY

09 JUL 2002

NEWPORT

09JUL02 E731909-1 D02934
P01/7700 0215823.6

1777

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

- Your reference 100748
- Patent application number 0215823.6 09 JUL 2002
(The Patent Office will fill in this part)
- Full name, address and postcode of the or of each applicant (underline all surnames) AstraZeneca AB
S-151 85 Sodertalje
Sweden
78 2244 8003
Patents ADP number (if you know it)
If the applicant is a corporate body, give the country/state of its incorporation Sweden
- Title of the invention QUINAZOLINE DERIVATIVES
- Name of your agent (if you have one) Tracey Bryant
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) AstraZeneca UK Limited
Global Intellectual Property
Mereside, Alderley Park
Macclesfield
Cheshire SK10 4TG
Patents ADP number (if you know it) 78224 71002
- If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

| Country | Priority application number (if you know it) | Date of filing (day / month / year) |
|---------|--|-------------------------------------|
|---------|--|-------------------------------------|
- If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

| Number of earlier application | Date of filing (day / month / year) |
|-------------------------------|-------------------------------------|
|-------------------------------|-------------------------------------|
- Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

| | |
|-------------|----|
| Description | 78 |
| Claim(s) | 01 |
| Abstract | 01 |

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Authorised Signatory

Date

8th July 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Jennifer C. Bennett - 01625 230148

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have finished the form you must remember to sign and date it.
- The details on the form must also be given to your agent or the Patent Office.

QUINOLINE DERIVATIVES

The invention concerns certain novel quinoline derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-tumour activity and are accordingly useful in methods of treatment of the human or animal body. The invention also concerns processes for the manufacture of said quinoline derivatives, pharmaceutical compositions containing them and their use in therapeutic methods, for example in the manufacture of medicaments for use in the prevention or treatment of solid tumour disease in a warm-blooded animal such as man.

Many of the current treatment regimes for cell proliferation diseases such as psoriasis and cancer utilise compounds which inhibit DNA synthesis. Such compounds are toxic to cells generally but their toxic effect on rapidly dividing cells such as tumour cells can be beneficial. Alternative approaches to anti-tumour agents which act by mechanisms other than the inhibition of DNA synthesis have the potential to display enhanced selectivity of action.

In recent years it has been discovered that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene *i.e.* a gene which, on activation, leads to the formation of malignant tumour cells (Bradshaw, Mutagenesis, 1986, 1, 91). Oncogenes give rise to the production of peptides which are receptors for growth factors. Activation of the growth factor receptor complex subsequently leads to an increase in cell proliferation. Oncogenes often encode abnormal versions of signal pathway components, such as receptor tyrosine kinases, serine-threonine kinases, or downstream signaling molecules such as the ras genes. The ras genes code for closely related small guanine nucleotide binding proteins which hydrolyse bound guanosine triphosphate (GTP) to guanosine diphosphate (GDP). Ras proteins are active in promoting cell growth and transformation when they are bound to GTP and inactive when they are bound to GDP. Transforming mutants of p21ras are defective in their GTPase activity and hence remain in the active GTP bound state. The ras oncogene is known to play an integral role in certain cancers and has been found to contribute to the formation of over 20% of all cases of human cancer.

When activated by ligand such as a growth factor, cell surface receptors which are coupled to the mitogenic response can initiate a chain of reactions which leads to the activation of guanine nucleotide exchange activity on ras proteins. When ras protein is in its active GTP-bound state, a number of other proteins interact directly with ras at the plasma membrane resulting in signal transmission through several distinct pathways. The best characterised effector protein is the product of the raf proto-oncogene. The interaction of raf

and ras is a key regulatory step in the control of cell proliferation. Ras-mediated activation of the raf serine-threonine kinase in turn activates the dual-specificity MEK (MEK1 and MEK2), which is the immediate upstream activator of mitogen activated protein kinase (MAPKs known as extracellular signal regulated protein kinases or ERK1 and ERK2). To date, no
5 substrates of MEK other than MAPK have been identified, though recent reports indicate that MEK may also be activated by other upstream signal proteins such as MEKK1 and Cot/Tpl-2. Activated MAPK translocates and accumulates in the nucleus, where it can phosphorylate and activate transcription factors such as Elk-1 and Sap1a, leading to the enhanced expression of genes such as c-fos.

10 The ras-dependent raf-MEK-MAPK cascade is one of the key signalling pathways responsible for transmitting and amplifying mitogenic signals from cell surface to the nucleus resulting in changes in gene expression and cell fate. This ubiquitous pathway appears essential for normal cell proliferation and constitutive activation of this pathway is sufficient to induce cellular transformation. Transforming mutants of p21ras are constitutively active,
15 resulting in raf, MEK and MAPK activity and cell transformation. Inhibition of MEK activity using either antisense raf, a dominant negative MEK mutant or the selective inhibitor PD098059 has been shown to block the growth and morphological transformation of ras-transformed fibroblasts.

The mechanism of activation of raf, MEK and MAPK is through phosphorylation on
20 specific serine, threonine or tyrosine residues. Activated raf and other kinases phosphorylate MEK1 on S218 and S222 and MEK2 on S222 and S226. This results in MEK activation and subsequent phosphorylation and activation of ERK1 on T190 and Y192 and ERK2 on T183 and Y185 by the dual specificity MEKs. Whilst MEK can be activated by a number of protein kinases, and active MAPKs phosphorylate and activate a number of substrate proteins
25 including transcription factors and other protein kinases, MEKs appear specific and sole activators of MAPKs and could act as a focal point for cross-cascade regulation. MEK1 and MEK2 isoforms show unusual specificity and also contain a proline-rich insert between catalytic subdomains IX and X which is not present in any of the other known MEK family members. These differences between MEK and other protein kinases, together with the
30 known role of MEK (MEK 1, MEK 2) and, more recently MEK 5, in proliferative signalling suggest it may be possible to discover and employ selective MEK inhibitors as therapeutic agents for use in proliferative disease

Accordingly, it has been recognised that an inhibitor of the MAPK kinase pathway should be of value as an anti-proliferative agent for use in the containment and/or treatment of solid tumour disease.

It is also known that several oncogenes encode tyrosine kinase enzymes and that certain growth factor receptors are also tyrosine kinase enzymes (Yarden *et al.*, Ann. Rev. Biochem., 1988, 57, 443; Larsen *et al.*, Ann. Reports in Med. Chem., 1989; Chpt. 13). The first group of tyrosine kinases to be identified arose from such viral oncogenes, for example pp60^{v-Src} tyrosine kinase (otherwise known as v-Src), and the corresponding tyrosine kinases in normal cells, for example pp60^{c-Src} tyrosine kinase (otherwise known as c-Src).

Receptor tyrosine kinases are important in the transmission of biochemical signals which initiate cell replication. Some of them are large enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor (EGF) and an intracellular portion which functions as a kinase to phosphorylate tyrosine amino acids in proteins and hence to influence cell proliferation. Various classes of receptor tyrosine kinases are known (Wilks, Advances in Cancer Research, 1993, 60, 43-73) based on families of growth factors which bind to different receptor tyrosine kinases. The classification includes Class I receptor tyrosine kinases comprising the EGF family of receptor tyrosine kinases such as the EGF, TGF α , Neu and erbB receptors, Class II receptor tyrosine kinases comprising the insulin family of receptor tyrosine kinases such as the insulin and IGF1 receptors and insulin-related receptor (IRR) and Class III receptor tyrosine kinases comprising the platelet-derived growth factor (PDGF) family of receptor tyrosine kinases such as the PDGF α , PDGF β and colony-stimulating factor 1 (CSF1) receptors.

It is also known that certain tyrosine kinases belong to the class of non-receptor tyrosine kinases which are located intracellularly and are involved in the transmission of biochemical signals such as those that influence tumour cell motility, dissemination and invasiveness and subsequently metastatic tumour growth (Ullrich *et al.*, Cell, 1990, 61, 203-212, Bolen *et al.*, FASEB J., 1992, 6, 3403-3409, Brickell *et al.*, Critical Reviews in Oncogenesis, 1992, 3, 401-406, Bohlen *et al.*, Oncogene, 1993, 8, 2025-2031, Courtneidge *et al.*, Semin. Cancer Biol., 1994, 5, 239-246, Lauffenburger *et al.*, Cell, 1996, 84, 359-369, Hanks *et al.*, BioEssays, 1996, 19, 137-145, Parsons *et al.*, Current Opinion in Cell Biology, 1997, 9, 187-192, Brown *et al.*, Biochimica et Biophysica Acta, 1996, 1287, 121-149 and Schlaepfer *et al.*, Progress in Biophysics and Molecular Biology, 1999, 71, 435-478). Various

classes of non-receptor tyrosine kinases are known including the Src family such as the Src, Lyn and Yes tyrosine kinases, the Abl family such as Abl and Arg and the Jak family such as Jak 1 and Tyk 2.

It is known that the Src family of non-receptor tyrosine kinases are highly regulated in normal cells and in the absence of extracellular stimuli are maintained in an inactive conformation. However, some Src family members, for example c-Src tyrosine kinase, are frequently significantly activated (when compared to normal cell levels) in common human cancers such as gastrointestinal cancer, for example colon, rectal and stomach cancer (Cartwright *et al.*, Proc. Natl. Acad. Sci. USA, 1990, 87, 558-562 and Mao *et al.*, Oncogene, 1997, 15, 3083-3090), and breast cancer (Muthuswamy *et al.*, Oncogene, 1995, 11, 1801-1810). The Src family of non-receptor tyrosine kinases has also been located in other common human cancers such as non-small cell lung cancers (NSCLCs) including adenocarcinomas and squamous cell cancer of the lung (Mazurenko *et al.*, European Journal of Cancer, 1992, 28, 372-7), bladder cancer (Fanning *et al.*, Cancer Research, 1992, 52, 1457-62), oesophageal cancer (Jankowski *et al.*, Gut, 1992, 33, 1033-8), cancer of the prostate, ovarian cancer (Wiener *et al.*, Clin. Cancer Research, 1999, 5, 2164-70) and pancreatic cancer (Lutz *et al.*, Biochem. and Biophys. Res. Comm., 1998, 243, 503-8). As further human tumour tissues are tested for the Src family of non-receptor tyrosine kinases it is expected that its widespread prevalence will be established.

It is further known that the predominant role of c-Src non-receptor tyrosine kinase is to regulate the assembly of focal adhesion complexes through interaction with a number of cytoplasmic proteins including, for example, focal adhesion kinase and paxillin. In addition c-Src is coupled to signalling pathways that regulate the actin cytoskeleton which facilitates cell motility. Likewise, important roles are played by the c-Src, c-Yes and c-Fyn non-receptor tyrosine kinases in integrin mediated signalling and in disrupting cadherin-dependent cell-cell junctions (Owens *et al.*, Molecular Biology of the Cell, 2000, 11, 51-64 and Klinghoffer *et al.*, EMBO Journal, 1999, 18, 2459-2471). Cellular motility is necessarily required for a localised tumour to progress through the stages of dissemination into the blood stream, invasion of other tissues and initiation of metastatic tumour growth. For example, colon tumour progression from localised to disseminated, invasive metastatic disease has been correlated with c-Src non-receptor tyrosine kinase activity (Brunton *et al.*, Oncogene, 1997, 14, 283-293, Fincham *et al.*, EMBO J., 1998, 17, 81-92 and Verbeek *et al.*, Exp. Cell Research, 1999, 248.

Accordingly it has been recognised that an inhibitor of such non-receptor tyrosine kinases should be of value as a selective inhibitor of the motility of tumour cells and as a selective inhibitor of the dissemination and invasiveness of mammalian cancer cells leading to inhibition of metastatic tumour growth. In particular an inhibitor of such non-receptor tyrosine kinases should be of value as an anti-invasive agent for use in the containment and/or treatment of solid tumour disease.

We have now found that surprisingly certain quinoline derivatives possess potent anti-tumour activity. It is believed that the compounds disclosed in the present invention provide an anti-tumour effect by way of inhibition of MEK enzymes that are involved in the MAPK kinase pathway and/or by way of inhibition of one or more of the non-receptor tyrosine-specific protein kinases that are involved in the signal transduction steps which lead to the invasiveness and migratory ability of metastasising tumour cells. In particular, it is believed that the compounds of the present invention provide an anti-tumour effect by inhibition of one or more of the MEK enzymes and/or by way of inhibition of the Src family of non-receptor tyrosine kinases, for example by inhibition of one or more of c-Src, c-Yes and c-Fyn. It is also known that c-Src non-receptor tyrosine kinase enzyme is involved in the control of osteoclast-driven bone resorption (Soriano *et al.*, Cell, 1991, 64, 693-702; Boyce *et al.*, J. Clin. Invest., 1992, 90, 1622-1627; Yoneda *et al.*, J. Clin. Invest., 1993, 91, 2791-2795 and Missbach *et al.*, Bone, 1999, 24, 437-49). An inhibitor of c-Src non-receptor tyrosine kinase is therefore of value in the prevention and treatment of bone diseases such as osteoporosis, Paget's disease, metastatic disease in bone and tumour-induced hypercalcaemia.

The compounds of the present invention are also useful in inhibiting the uncontrolled cellular proliferation which arises from various non-malignant diseases such as inflammatory diseases (for example rheumatoid arthritis and inflammatory bowel disease), fibrotic diseases (for example hepatic cirrhosis and lung fibrosis), glomerulonephritis, multiple sclerosis, psoriasis, hypersensitivity reactions of the skin, blood vessel diseases (for example atherosclerosis and restenosis), allergic asthma, insulin-dependent diabetes, diabetic retinopathy and diabetic nephropathy.

The compounds of the invention may possess inhibitory activity against the MEK enzymes that are involved in the MAPK kinase pathway. They may also possess an inhibitory activity against the Src family of non-receptor tyrosine kinases. Generally the compounds of the present invention may also possess potent inhibitory activity against the Src family of non-


receptor tyrosine kinases, for example by inhibition of c-Src and/or c-Yes, whilst possessing less potent inhibitory activity against other tyrosine kinase enzymes such as the receptor tyrosine kinases, for example EGF receptor tyrosine kinase and/or VEGF receptor tyrosine kinase.

5 It is stated in International Patent Application WO 98/43960 that a range of 3-cyanoquinoline derivatives are useful in the treatment of cancer. Certain of the compounds are stated to be inhibitors of the mitogen-activated protein kinase (MAPK) pathway, others are stated to be inhibitors of EGF receptor tyrosine kinase, and others are stated to be inhibitors of growth factors such as vascular endothelial growth factor (VEGF). There is no disclosure
10 therein of any 1,3-benzodioxol-4-yl-containing 3-cyanoquinoline derivatives.

It is stated in International Patent Application WO 00/68201 that a range of 3-cyanoquinoline derivatives are also useful in the treatment of cancer. Certain of the compounds are stated to be inhibitors of MEK, a MAPK kinase. There is no disclosure therein of any 1,3-benzodioxol-4-yl-containing 3-cyanoquinoline derivatives.

15 It is disclosed in Journal Medicinal Chemistry, 2001, 44, 822-833 that certain 4-anilino-3-cyanoquinoline derivatives are useful for the inhibition of Src-dependent cell proliferation. There is no disclosure therein of any 1,3-benzodioxol-4-yl-containing 3-cyanoquinoline derivatives.


According to one aspect of the invention there is provided a quinoline derivative of the
20 Formula I



25 wherein Z^1 is an O, S, SO, SO₂, N(R²) or C(R²)₂ group, wherein each R² group, which may be the same or different, is hydrogen or (1-6C)alkyl;


m is 0, 1, 2, 3 or 4;

each R^1 group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :



wherein X^1 is a direct bond or is selected from O, S, SO, SO₂, N(R⁴), CO, CH(OR⁴), CON(R⁴), N(R⁴)CO, SO₂N(R⁴), N(R⁴)SO₂, OC(R⁴)₂, SC(R⁴)₂ and N(R⁴)C(R⁴)₂, wherein R⁴ is hydrogen or (1-6C)alkyl, and Q¹ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or (R¹)_m is (1-3C)alkylenedioxy, and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO₂, N(R⁵), CO, CH(OR⁵), CON(R⁵), N(R⁵)CO, SO₂N(R⁵), N(R⁵)SO₂, CH=CH and C≡C wherein R⁵ is hydrogen or (1-6C)alkyl or, when the inserted group is N(R⁵), R⁵ may also be (2-6C)alkanoyl,


and wherein any CH₂=CH- or HC≡C- group within a R¹ substituent optionally bears at the terminal CH₂= or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :



wherein X^2 is a direct bond or is selected from CO and N(R⁶)CO, wherein R⁶ is hydrogen or (1-6C)alkyl, and Q² is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,


and wherein any CH, CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH, CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a

substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, 5 N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :



wherein X^3 is a direct bond or is selected from O, S, SO, SO₂, N(R⁷), CO, CH(OR⁷), 10 CON(R⁷), N(R⁷)CO, SO₂N(R⁷), N(R⁷)SO₂, C(R⁷)₂O, C(R⁷)₂S and N(R⁷)C(R⁷)₂, wherein R⁷ is hydrogen or (1-6C)alkyl, and Q³ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R¹ 15 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, 20 N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :



25 wherein X^4 is a direct bond or is selected from O and N(R⁹), wherein R⁹ is hydrogen or (1-6C)alkyl, and R⁸ is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl or from a group of the formula :

30 $-X^5-Q^4$


wherein X^5 is a direct bond or is selected from O, N(R¹⁰) and CO, wherein R¹⁰ is hydrogen or (1-6C)alkyl, and Q⁴ is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same

or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo or thioxo substituents;

5 n is 0, 1, 2 or 3;

each R^3 group is halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N -(1-6C)alkylcarbamoyl, 10 N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N -(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N -(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N -(1-6C)alkyl-(3-6C)alkynoylamino, N -(1-6C)alkylsulphamoyl, N,N -di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N -(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :



15


wherein X^6 is a direct bond or is selected from O and $N(R^{12})$, wherein R^{12} is hydrogen or (1-6C)alkyl, and R^{11} is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl;

20

Z^2 is a $C\equiv C$ or $C(R^{13})=C(R^{13})$ group, wherein each R^{13} group, which may be the same or different, is hydrogen or (1-6C)alkyl; and

R^{14} is selected from halogeno, cyano, isocyano, formyl, carboxy, carbamoyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxycarbonyl, N -(1-6C)alkylcarbamoyl, N,N -di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, N -(1-6C)alkylsulphamoyl, 25 N,N -di-[(1-6C)alkyl]sulphamoyl, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl,


(1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl or from a group of the formula :



30 wherein X^7 is a direct bond or is selected from CO, $CH(OR^{15})$, $CON(R^{15})$ or $SO_2N(R^{15})$, wherein R^{15} is hydrogen or (1-6C)alkyl, and Q^5 is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl,

(3-7C)cycloalkyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any CH, CH₂ or CH₃ group within a R¹⁴ substituent optionally bears on each said CH, CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a
 5 substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl,
 10 N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :



wherein X⁸ is a direct bond or is selected from O, S, SO, SO₂, N(R¹⁶), CO, CH(OR¹⁶), CON(R¹⁶), N(R¹⁶)CO, SO₂N(R¹⁶), N(R¹⁶)SO₂, C(R¹⁶)₂O, C(R¹⁶)₂S and N(R¹⁶)C(R¹⁶)₂,
 15 wherein R¹⁶ is hydrogen or (1-6C)alkyl, and Q⁶ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,


and wherein the N in any carbamoyl group within a substituent on R¹⁴ bears at least one substituent selected from

20 and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R¹⁴ optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino,
 25 di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :



30 wherein X⁹ is a direct bond or is selected from O and N(R¹⁸), wherein R¹⁸ is hydrogen or (1-6C)alkyl, and R¹⁷ is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-

(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl,
or from a group of the formula :



wherein X^{10} is a direct bond or is selected from O, $N(R^{19})$ and CO, wherein R^{19} is hydrogen or
5 (1-6C)alkyl, and Q^7 is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl
or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same
or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and
(1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1 or 2
10 oxo or thioxo substituents;
or a pharmaceutically-acceptable salt thereof.

In this specification the generic term "alkyl" includes both straight-chain and
branched-chain alkyl groups such as propyl, isopropyl and tert-butyl, and also
(3-7C)cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and
15 cycloheptyl. However references to individual alkyl groups such as "propyl" are specific for
the straight-chain version only, references to individual branched-chain alkyl groups such as
"isopropyl" are specific for the branched-chain version only and references to individual
cycloalkyl groups such as "cyclopentyl" are specific for that 5-membered ring only. An
analogous convention applies to other generic terms, for example (1-6C)alkoxy includes
20 methoxy, ethoxy, cyclopropyloxy and cyclopentyloxy, (1-6C)alkylamino includes
methylamino, ethylamino, cyclobutylamino and cyclohexylamino, and di-[(1-6C)alkyl]amino
includes dimethylamino, diethylamino, N-cyclobutyl-N-methylamino and N-cyclohexyl-
N-ethylamino.

It is to be understood that, insofar as certain of the compounds of Formula I defined
25 above may exist in optically active or racemic forms by virtue of one or more asymmetric
carbon atoms, the invention includes in its definition any such optically active or racemic form
which possesses the above-mentioned activity. The synthesis of optically active forms may be
carried out by standard techniques of organic chemistry well known in the art, for example by
synthesis from optically active starting materials or by resolution of a racemic form.
30 Similarly, the above-mentioned activity may be evaluated using the standard laboratory
techniques referred to hereinafter.

Suitable values for the generic radicals referred to above include those set out below.

A suitable value for any one of the 'Q' groups (Q^1 to Q^7) when it is aryl or for the aryl group within a 'Q' group is, for example, phenyl or naphthyl, preferably phenyl.

A suitable value for any one of the 'Q' groups (Q^1 , Q^3 , Q^5 or Q^6) when it is (3-7C)cycloalkyl or for the (3-7C)cycloalkyl group within a 'Q' group is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or bicyclo[2.2.1]heptyl and a suitable value for any one of the 'Q' groups (Q^1 , Q^3 or Q^6) when it is (3-7C)cycloalkenyl or for the (3-7C)cycloalkenyl group within a 'Q' group is, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl.

A suitable value for any one of the 'Q' groups (Q^1 to Q^7) when it is heteroaryl or for the heteroaryl group within a 'Q' group is, for example, an aromatic 5- or 6-membered monocyclic ring or a 9- or 10-membered bicyclic ring with up to five ring heteroatoms selected from oxygen, nitrogen and sulphur, for example furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl.


A suitable value for any one of the 'Q' groups (Q^1 to Q^7) when it is heterocyclyl or for the heterocyclyl group within a 'Q' group is, for example, a non-aromatic saturated or partially saturated 3 to 10 membered monocyclic or bicyclic ring with up to five heteroatoms selected from oxygen, nitrogen and sulphur, for example oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepanyl, tetrahydrothienyl, 1,1-dioxotetrahydrothienyl, tetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, azetidiny, pyrrolinyl, pyrrolidinyl, morpholinyl, tetrahydro-1,4-thiazinyl, 1,1-dioxotetrahydro-1,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl or tetrahydropyrimidinyl, preferably tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, 1,1-dioxotetrahydro-4H-1,4-thiazinyl, piperidinyl or piperazinyl. A suitable value for such a group which bears 1 or 2 oxo or thioxo substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.

A suitable value for a 'Q' group when it is heteroaryl-(1-6C)alkyl is, for example, heteroarylmethyl, 2-heteroarylethyl and 3-heteroarylpropyl. The invention comprises corresponding suitable values for 'Q' groups when, for example, rather than a

heteroaryl-(1-6C)alkyl group, an aryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl-(1-6C)alkyl or heterocyclyl-(1-6C)alkyl group is present.

In structural Formula I there is a hydrogen atom at the 2-position on the quinoline ring. It is to be understood thereby that the R^1 substituents may only be located at the 5-, 6-, 7- or 8-positions on the quinoline ring *i.e.* that the 2-position remains unsubstituted. It is further to be understood that the R^3 group that may be present on the 1,3-benzodioxol-4-yl group within structural Formula I may be located on the phenyl ring or on the methylene group within the dioxol group. Preferably, any R^3 group that is present on the 1,3-benzodioxol-4-yl group within structural Formula I is located on the phenyl ring thereof. It is further to be understood that the $-Z^2-R^{14}$ group within structural Formula I may only be located on the phenyl ring within the 1,3-benzodioxol-4-yl group.

For the avoidance of doubt, the positions on structural Formula I are numbered as follows:



15

Suitable values for any of the 'R' groups (R^1 to R^{19}) or for various groups within an

R^1 , R^3 or R^{14} group include :-

- | | |
|---------------------------|--|
| for halogeno | fluoro, chloro, bromo and iodo; |
| for (1-6C)alkyl: | methyl, ethyl, propyl, isopropyl and <u>tert</u> -butyl; |
| 20 for (2-8C)alkenyl: | vinyl, isopropenyl, allyl and but-2-enyl; |
| for (2-8C)alkynyl: | ethynyl, 2-propynyl and but-2-ynyl; |
| for (1-6C)alkoxy: | methoxy, ethoxy, propoxy, isopropoxy and butoxy; |
| for (2-6C)alkenyloxy: | vinylloxy and allyloxy; |
| for (2-6C)alkynyloxy: | ethynyloxy and 2-propynyloxy; |
| 25 for (1-6C)alkylthio: | methylthio, ethylthio and propylthio; |
| for (1-6C)alkylsulphinyl: | methylsulphinyl and ethylsulphinyl; |

- for (1-6C)alkylsulphonyl: methylsulphonyl and ethylsulphonyl;
- for (1-6C)alkylamino: methylamino, ethylamino, propylamino, isopropylamino and butylamino;
- for di-[(1-6C)alkyl]amino: dimethylamino, diethylamino, N-ethyl-
 5 N-methylamino and diisopropylamino;
- for (1-6C)alkoxycarbonyl: methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and tert-butoxycarbonyl;
- for N-(1-6C)alkylcarbamoyl: N-methylcarbamoyl, N-ethylcarbamoyl and N-propylcarbamoyl;
- 10 for N,N-di-[(1-6C)alkyl]carbamoyl: N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl and N,N-diethylcarbamoyl;
- for (2-6C)alkanoyl: acetyl and propionyl;
- for (2-6C)alkanoyloxy: acetoxy and propionyloxy;
- for (2-6C)alkanoylamino: acetamido and propionamido;
- 15 for N-(1-6C)alkyl-(2-6C)alkanoylamino: N-methylethylacetamido and N-methylpropionamido;
- for N-(1-6C)alkylsulphamoyl: N-methylsulphamoyl and N-ethylsulphamoyl;
- for N,N-di-[(1-6C)alkyl]sulphamoyl: N,N-dimethylsulphamoyl;
- for (1-6C)alkanesulphonylamino: methanesulphonylamino and ethanesulphonylamino;
- for N-(1-6C)alkyl-(1-6C)alkanesulphonylamino: N-methylmethanesulphonylamino and
 20 N-methylethanesulphonylamino;
- for (3-6C)alkenoylamino: acrylamido, methacrylamido and crotonamido;
- for N-(1-6C)alkyl-(3-6C)alkenoylamino: N-methylacrylamido and N-methylcrotonamido;
- for (3-6C)alkynoylamino: propiolamido;
- for N-(1-6C)alkyl-(3-6C)alkynoylamino: N-methylpropiolamido;
- 25 for amino-(1-6C)alkyl: aminomethyl, 2-aminoethyl, 1-aminoethyl and 3-aminopropyl;
- for (1-6C)alkylamino-(1-6C)alkyl: methylaminomethyl, ethylaminomethyl, 1-methylaminoethyl, 2-methylaminoethyl, 2-ethylaminoethyl and 3-methylaminopropyl;
- 30 for di-[(1-6C)alkyl]amino-(1-6C)alkyl: dimethylaminomethyl, diethylaminomethyl, 1-dimethylaminoethyl, 2-dimethylaminoethyl and 3-dimethylaminopropyl;
- for halogeno-(1-6C)alkyl: chloromethyl, 2-chloroethyl, 1-chloroethyl and

- for hydroxy-(1-6C)alkyl: 3-chloropropyl;
hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl and
3-hydroxypropyl;
- for (1-6C)alkoxy-(1-6C)alkyl: methoxymethyl, ethoxymethyl, 1-methoxyethyl,
2-methoxyethyl, 2-ethoxyethyl and
3-methoxypropyl;
- for cyano-(1-6C)alkyl: cyanomethyl, 2-cyanoethyl, 1-cyanoethyl and
3-cyanopropyl;
- for (2-6C)alkanoylamino-(1-6C)alkyl: acetamidomethyl, propionamidomethyl and
2-acetamidoethyl; and
- for (1-6C)alkoxycarbonylamino-(1-6C)alkyl: methoxycarbonylaminomethyl,
ethoxycarbonylaminomethyl,
tert-butoxycarbonylaminomethyl and
2-methoxycarbonylaminoethyl.

15 A suitable value for $(R^1)_m$ when it is a (1-3C)alkylenedioxy group is, for example, methylenedioxy or ethylenedioxy and the oxygen atoms thereof occupy adjacent ring positions.

When, as defined hereinbefore, an R^1 group forms a group of the formula Q^1-X^1 - and, for example, X^1 is a $OC(R^4)_2$ linking group, it is the carbon atom, not the oxygen atom, of the
20 $OC(R^4)_2$ linking group which is attached to the quinoline ring and the oxygen atom is attached to the Q^1 group. Similarly, when, for example a CH_3 group within a R^1 substituent bears a group of the formula $-X^3-Q^3$ and, for example, X^3 is a $C(R^7)_2O$ linking group, it is the carbon atom, not the oxygen atom, of the $C(R^7)_2O$ linking group which is attached to the CH_3 group and the oxygen atom is linked to the Q^3 group. A similar convention applies to the attachment
25 of the groups of the formulae Q^3-X^3 -, and $-X^8-Q^6$.

As defined hereinbefore, adjacent carbon atoms in any (2-6C)alkylene chain within a R^1 substituent may be optionally separated by the insertion into the chain of a group such as O, $CON(R^5)$ or $C\equiv C$. For example, insertion of a $C\equiv C$ group into the ethylene chain within a 2-morpholinoethoxy group gives rise to a 4-morpholinobut-2-ynyloxy group and, for example,
30 insertion of a CONH group into the ethylene chain within a 3-methoxypropoxy group gives rise to, for example, a 2-(2-methoxyacetamido)ethoxy group.


When, as defined hereinbefore, any CH , CH_2 or CH_3 group within a R^1 or R^{14} substituent optionally bears on each said CH , CH_2 or CH_3 group a substituent as defined

hereinbefore, suitable R^1 or R^{14} substituents so formed include, for example, hydroxy-substituted heterocyclyl-(1-6C)alkoxy groups such as 2-hydroxy-3-piperidinopropoxy and 2-hydroxy-3-morpholinopropoxy.

A suitable pharmaceutically-acceptable salt of a compound of the Formula I is, for example, an acid-addition salt of a compound of the Formula I, for example an acid-addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric, trifluoroacetic, citric or maleic acid; or, for example, a salt of a compound of the Formula I which is sufficiently acidic, for example an alkali or alkaline earth metal salt such as a calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

Particular novel compounds of the invention include, for example, quinoline derivatives of the Formula I, or pharmaceutically-acceptable salts thereof, wherein, unless otherwise stated, each of Z^1 , m, R^1 , n, R^3 , Z^2 and R^{14} has any of the meanings defined hereinbefore or in paragraphs (a) to (v) hereinafter :-

- (a) Z^1 is O, S, SO, SO_2 , CH_2 or NH;
- (b) Z^1 is O;
- (c) Z^1 is NH;
- (d) R^1 substituents may only be located at the 5-, 6- and/or 7-positions on the quinoline ring *i.e.* the 2- and 8-positions remain unsubstituted;
- (e) R^1 substituents may only be located at the 6- and/or 7-positions on the quinoline ring *i.e.* the 2-, 5- and 8-positions remain unsubstituted;
- (f) m is 1 or 2, and each R^1 group, which may be the same or different, is selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino and N-(1-6C)alkyl-(3-6C)alkynoylamino or from a group of the formula :



wherein X^1 is a direct bond or is selected from O, $N(R^4)$, $CON(R^4)$, $N(R^4)CO$ and $OC(R^4)_2$ wherein R^4 is hydrogen or (1-6C)alkyl, and Q^1 is aryl, aryl-(1-6C)alkyl, cycloalkyl-, (1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl


and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R^1 substituent are optionally separated by the insertion into the chain of a group selected from O, $N(R^5)$, $CON(R^5)$, $N(R^5)CO$, $CH=CH$ and $C\equiv C$ wherein R^5 is hydrogen or (1-6C)alkyl, or, when the inserted group is $N(R^5)$, R^5 may also be (2-6C)alkanoyl,

- 5 and wherein any $CH_2=CH-$ or $HC\equiv C-$ group within a R^1 substituent optionally bears at the terminal $CH_2=$ or $HC\equiv$ position a substituent selected from carbamoyl, N -(1-6C)alkylcarbamoyl, N,N -di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :




wherein X^2 is a direct bond or is CO or $N(R^6)CO$, wherein R^6 is hydrogen or (1-6C)alkyl, and Q^2 is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

- and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group one or more halogeno groups or a substituent selected from hydroxy, 15 amino, (1-6C)alkoxy, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N -(1-6C)alkyl-(2-6C)alkanoylamino or from a group of the formula :




- wherein X^3 is a direct bond or is selected from O, $N(R^6)$, $CON(R^7)$, $N(R^7)CO$ and $C(R^7)_2O$, 20 wherein R^7 is hydrogen or (1-6C)alkyl, and Q^3 is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

- and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^1 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, 25 (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylsulphonyl, N -(1-6C)alkylcarbamoyl, N,N -di-[(1-6C)alkyl]carbamoyl and (2-6C)alkanoyl, or optionally bears 1 substituent selected from a group of the formula :



- wherein X^4 is a direct bond or is selected from O and $N(R^9)$, wherein R^9 is hydrogen or 30 (1-6C)alkyl, and R^8 is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,


di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl,
(1-6C)alkoxycarbonylamino-(1-6C)alkyl or from a group of the formula :



wherein X^5 is a direct bond or is selected from O, $N(R^{10})$ and CO, wherein R^{10} is hydrogen or
5 (1-6C)alkyl, and Q^4 is heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2
substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and
(1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2
oxo substituents;

10 (g) m is 1 or 2, and each R^1 group, which may be the same or different, is selected from
fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, propyl, butyl, vinyl,
allyl, but-3-enyl, pent-4-enyl, hex-5-enyl, ethynyl, 2-propynyl, but-3-ynyl, pent-4-ynyl,
hex-5-ynyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, allyloxy, but-3-enyloxy,
pent-4-enyloxy, hex-5-enyloxy, ethynyloxy, 2-propynyloxy, but-3-ynyloxy, pent-4-ynyloxy,
15 hex-5-ynyloxy, methylamino, ethylamino, propylamino, dimethylamino, diethylamino,
dipropylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl, acetamido, propionamido,
acrylamido and propiolamido or from a group of the formula :




wherein X^1 is a direct bond or is selected from O, NH, CONH, NHCO and OCH_2 and Q^1 is
20 phenyl, benzyl, cyclopropylmethyl, 2-thienyl, 1-imidazolyl, 1,2,3-triazol-1-yl,
1,2,4-triazol-1-yl, 2-, 3- or 4-pyridyl, 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl,
2-(1,2,3-triazolyl)ethyl, 3-(1,2,3-triazolyl)propyl, 2-(1,2,4-triazolyl)ethyl,
3-(1,2,4-triazolyl)propyl, 2-, 3- or 4-pyridylmethyl, 2-(2-, 3- or 4-pyridyl)ethyl,
3-(2-, 3- or 4-pyridyl)propyl, tetrahydrofuran-3-yl, 3- or 4-tetrahydropyranyl,
25 1-, 2- or 3-pyrrolidinyl, morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino,
piperidin-3-yl, piperidin-4-yl, 1-, 3- or 4-homopiperidinyl, piperazin-1-yl, homopiperazin-1-yl,
1-, 2- or 3-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl,
3- or 4-piperidinylmethyl, 1-, 3- or 4-homopiperidinylmethyl, 2-pyrrolidin-1-ylethyl,
3-pyrrolidin-2-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-1-ylpropyl,
30 4-pyrrolidin-1-ylbutyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl,
2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-
4-yl)propyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, 2-piperidin-3-ylethyl,
3-piperidin-2-ylpropyl, 2-piperidin-1-ylethyl, 3-piperidin-4-ylpropyl

2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl,
3-piperazin-1-ylpropyl, 4-piperazin-1-ylbutyl, 2-homopiperazin-1-ylethyl or
3-homopiperazin-1-ylpropyl,


and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R^1 substituent
5 are optionally separated by the insertion into the chain of a group selected from O, NH,
N(Me), CONH, NHCO, CH=CH and C≡C,

and wherein any $CH_2=CH-$ or $HC\equiv C-$ group within a R^1 substituent optionally bears at
the terminal $CH_2=$ or $HC\equiv$ position a substituent selected from carbamoyl,
N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N,N-dimethylcarbamoyl,
10 N-aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, methylaminomethyl,
2-methylaminoethyl, 3-methylaminopropyl, 4-methylaminobutyl, dimethylaminomethyl,
2-dimethylaminoethyl, 3-dimethylaminopropyl or 4-dimethylaminobutyl, or from a group of
the formula :



15 wherein X^2 is a direct bond or is CO, NHCO or N(Me)CO and Q^2 is pyridyl, pyridylmethyl,
2-pyridylethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl,
piperidin-4-yl, piperazin-1-yl, pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl,
3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl,
3-pyrrolidin-2-ylpropyl, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl,
20 4-morpholinobutyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl,
4-piperidinobutyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl,
2-piperidin-4-ylethyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl or
4-piperazin-1-ylbutyl,

and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each
25 said CH_2 or CH_3 group one or more fluoro or chloro groups or a substituent selected from
hydroxy, amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diisopropylamino,
N-ethyl-N-methylamino, N-isopropyl-N-methylamino, N-methyl-N-propylamino, acetoxo,
acetamido and N-methylacetamido or from a group of the formula :




30 wherein X^3 is a direct bond or is selected from O, NH, CONH, NHCO and CH_2O and Q^3 is
pyridyl, pyridylmethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl,
piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-

2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,

- 5 and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R¹ optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, allyl, 2-propynyl, methoxy, methylsulphonyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl and acetyl or optionally bears 1 substituent selected from a group of the formula :




- wherein X⁴ is a direct bond or is selected from O and NH and R⁸ is 2-fluoroethyl, 3-fluoropropyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-ethylaminoethyl, 3-ethylaminopropyl, 15 dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, acetamidomethyl, methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl, tert-butoxycarbonylaminomethyl or a group of the formula :



- wherein X⁵ is a direct bond or is selected from O, NH and CO and Q⁴ is 20 pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, each of which optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy,

- 25 and wherein any heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 oxo substituents;

- (h) m is 1 or 2, and each R¹ group, which may be the same or different, is selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, 30 N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino or from a group of the formula :



wherein X^1 is selected from O, $N(R^4)$, $CON(R^4)$, $N(R^4)CO$ and $OC(R^4)_2$ wherein R^4 is hydrogen or (1-6C)alkyl, and Q^1 is aryl, aryl-(1-6C)alkyl, cycloalkyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or X^1 is a direct bond and Q^1 is aryl-(1-6C)alkyl, cycloalkyl-(1-6C)alkyl, heteroaryl-(1-6C)alkyl or

5 heterocyclyl-(1-6C)alkyl,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R^1 substituent are optionally separated by the insertion into the chain of a group selected from O, $N(R^5)$, $CON(R^5)$, $N(R^5)CO$, $CH=CH$ and $C\equiv C$ wherein R^5 is hydrogen or (1-6C)alkyl, or, when the inserted group is $N(R^5)$, R^5 may also be (2-6C)alkanoyl,

10 and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group one or more halogeno groups or a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino or a group of the formula :

15 $-X^3-Q^3$

wherein X^3 is a direct bond or is selected from O, $N(R^6)$, $CON(R^7)$, $N(R^7)CO$ and $C(R^7)_2O$, wherein R^7 is hydrogen or (1-6C)alkyl, and Q^3 is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^1
 20 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylsulphonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl and (2-6C)alkanoyl, or optionally bears 1 substituent selected from a group of the formula :

25 $-X^4-R^8$

wherein X^4 is a direct bond or is selected from O and $N(R^9)$, wherein R^9 is hydrogen or (1-6C)alkyl, and R^8 is hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl or from a group

30 of the formula :

$-X^5-Q^4$

wherein X^5 is a direct bond or is selected from O, $N(R^{10})$ and CO, wherein R^{10} is hydrogen or (1-6C)alkyl, and Q^4 is heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2

substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 oxo substituents;

- 5 (i) m is 1 or 2, and each R¹ group, which may be the same or different, is selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methylamino, ethylamino, propylamino, dimethylamino, diethylamino, dipropylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl, acetamido, propionamido, acrylamido, propiolamido or from a group of the formula :




wherein X¹ is selected from O, NH, CONH, NHCO and OCH₂ and Q¹ is phenyl, benzyl, cyclopropylmethyl, 2-thienyl, 1-imidazolyl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 2-, 3- or 4-pyridyl, 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl, 2-(1,2,3-triazolyl)ethyl, 3-(1,2,3-triazolyl)propyl, 2-(1,2,4-triazolyl)ethyl, 3-(1,2,4-triazolyl)propyl, 2-, 3- or 4-pyridylmethyl, 2-(2-, 3- or 4-pyridyl)ethyl, 3-(2-, 3- or 4-pyridyl)propyl, tetrahydrofuran-3-yl, 3- or 4-tetrahydropyranyl, 1-, 2- or 3-pyrrolidinyl, morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yl, piperidin-4-yl, 1-, 3- or 4-homopiperidinyl, piperazin-1-yl, homopiperazin-1-yl, 1-, 2- or 3-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 3- or 4-piperidinylmethyl, 1-, 3- or 4-homopiperidinylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, 2-piperidin-3-ylethyl, 3-piperidin-3-ylpropyl, 2-piperidin-4-ylethyl, 3-piperidin-4-ylpropyl, 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl, 4-piperazin-1-ylbutyl, 2-homopiperazin-1-ylethyl or 3-homopiperazin-1-ylpropyl, or wherein X¹ is a direct bond and Q¹ is benzyl, cyclopropylmethyl, 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl, 2-(1,2,3-triazolyl)ethyl, 3-(1,2,3-triazolyl)propyl, 2-(1,2,4-triazolyl)ethyl, 3-(1,2,4-triazolyl)propyl, 2-, 3- or 4-pyridylmethyl, 2-(2-, 3- or 4-pyridyl)ethyl, 3-(2-, 3- or 4-pyridyl)propyl, 1-, 2- or 3-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 3- or 4-piperidinylmethyl.

1-, 3- or 4-homopiperidinylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-2-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, 2-piperidin-3-ylethyl, 3-piperidin-3-ylpropyl, 2-piperidin-4-ylethyl, 3-piperidin-4-ylpropyl, 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl, 4-piperazin-1-ylbutyl, 2-homopiperazin-1-ylethyl or 3-homopiperazin-1-ylpropyl,


10 and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, NH, N(Me), CONH, NHCO, CH=CH and C≡C,

and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more fluoro or chloro groups or a substituent selected from 15 hydroxy, amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diisopropylamino, N-ethyl-N-methylamino, N-isopropyl-N-methylamino, N-methyl-N-propylamino, acetoxy, acetamido, N-methylacetamido or from a group of the formula :



wherein X³ is a direct bond or is selected from O, NH, CONH, NHCO and CH₂O and Q³ is 20 pyridyl, pyridylmethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-piperazin-1-ylethyl or 3-piperazin-25 1-ylpropyl,


and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R¹ optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, allyl, 2-propynyl, methoxy, methylsulphonyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl and acetyl, 30 or optionally bears 1 substituent selected from a group of the formula :



wherein X⁴ is a direct bond or is selected from O and NH and R⁸ is 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, aminomethyl,

2-aminoethyl, 3-aminopropyl, methylaminomethyl, 2-methylaminoethyl,
 3-methylaminopropyl, 2-ethylaminoethyl, 3-ethylaminopropyl, dimethylaminomethyl,
 2-dimethylaminoethyl, 3-dimethylaminopropyl, acetamidomethyl,
 methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl,

5 tert-butoxycarbonylaminomethyl or from a group of the formula :



wherein X^5 is a direct bond or is selected from O, NH and CO and Q^4 is

pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, morpholinomethyl,
 2-morpholinoethyl, 3-morpholinopropyl, piperidinomethyl, 2-piperidinoethyl,
 10 3-piperidinopropyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,
 each of which optionally bears 1 or 2 substituents, which may be the same or different,
 selected from fluoro, chloro, methyl and methoxy,
 and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo
 substituents;

15 (j) m is 2 and each R^1 group, which may be the same or different, is located at the 5- and
 7-positions or at the 6- and 7-positions and R^1 is selected from hydroxy, amino, methyl, ethyl,
 propyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentyloxy, methylamino, ethylamino,
 dimethylamino, diethylamino, acetamido, propionamido, cyclopentyloxy, cyclohexyloxy,
 phenoxy, benzyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-
 20 yloxy, cyclopropylmethoxy, 2-imidazol-1-ylethoxy, 3-imidazol-1-ylpropoxy,
 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, 2-(1,2,4-triazol-1-yl)ethoxy,
 3-(1,2,4-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, pyrid-4-ylmethoxy,
 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy,
 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,
 25 4-pyrrolidin-1-ylbutoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,
 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy,
 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-
 4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy,
 piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy,
 30 2-piperidin-3-ylethoxy, 3-piperidin-3-ylpropoxy, 2-piperidin-4-ylethoxy,
 3-piperidin-4-ylpropoxy, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy,
 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 4-piperazin-1-ylbutoxy,
 2-homopiperazin-1-ylethoxy, 3-homopiperazin-1-ylpropoxy, 2-pyrrolidin-1-ylethylamino,

3-pyrrolidin-1-ylpropylamino, 4-pyrrolidin-1-ylbutylamino, pyrrolidin-3-ylamino, pyrrolidin-2-ylmethylamino, 2-pyrrolidin-2-ylethylamino, 3-pyrrolidin-2-ylpropylamino, 2-morpholinoethylamino, 3-morpholinopropylamino, 4-morpholinobutylamino, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethylamino, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propylamino, 2-piperidinoethylamino, 3-piperidinopropylamino, 4-piperidinobutylamino, piperidin-3-ylamino, piperidin-4-ylamino, piperidin-3-ylmethylamino, 2-piperidin-3-ylethylamino, piperidin-4-ylmethylamino, 2-piperidin-4-ylethylamino, 2-homopiperidin-1-ylethylamino, 3-homopiperidin-1-ylpropylamino, 2-piperazin-1-ylethylamino, 3-piperazin-1-ylpropylamino, 4-piperazin-1-ylbutylamino, 2-homopiperazin-1-ylethylamino or 3-homopiperazin-1-ylpropylamino,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, NH, N(Me), CH=CH and C≡C,

and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more fluoro or chloro groups or a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diisopropylamino, N-ethyl-N-methylamino, N-isopropyl-N-methylamino, N-methyl-N-propylamino, acetoxy, acetamido and N-methylacetamido,


and wherein any phenyl, imidazolyl, triazolyl, pyridyl or heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl and methoxy, and a pyrrolidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl or homopiperazin-1-yl group within a R¹ substituent is optionally N-substituted with allyl, 2-propynyl, methylsulphonyl, acetyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, 2-aminoethyl, 3-aminopropyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, the last 8 of which substituents each optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy,

and wherein any heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 oxo substituents;

(k) n is 0;

(l) n is 1 or 2 and the R³ groups, which may be the same or different, are located at the 5- and/or 6-positions of the 1,3-benzodioxol-4-yl group and are selected from halogeno, trifluoromethyl, cyano, hydroxy, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl,

5 (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl or from a group of the formula :



wherein X⁶ is a direct bond and R¹¹ is hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or

10 di-[(1-6C)alkyl]amino-(1-6C)alkyl;

(m) n is 1 or 2 and the R³ groups, which may be the same or different, are located at the 5- and/or 6-positions of the 1,3-benzodioxol-4-yl group and are selected from halogeno, trifluoromethyl, cyano, hydroxy, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy;

(n) n is 1 or 2 and the R³ groups, which may be the same or different, are located at the 15 5- and/or 6-positions of the 1,3-benzodioxol-4-yl group and are selected from fluoro, chloro, bromo, iodo, trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl, isopropenyl, ethynyl, 1-propynyl, 2-propynyl, methoxy and ethoxy;

(o) n is 1 and the R³ group is located at the 5- or 6-position of the 1,3-benzodioxol-4-yl group, especially the 5-position, and is selected from chloro, bromo,

20 trifluoromethyl, cyano, hydroxy, methyl, ethyl, methoxy and ethoxy;

(p) the -Z²-R¹⁴ group is located at the 7- or 6-position on the 1,3-benzodioxol-4-yl group;

(q) the -Z²-R¹⁴ group is located at the 7-position on the 1,3-benzodioxol-4-yl group;

(r) Z² is a C≡C group;

(s) Z² is a CH=CH group;


25 (t) R¹⁴ is selected from halogeno, cyano, formyl, carboxy, carbamoyl,

(1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl,

(2-6C)alkanoyl, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl,

halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl,


30 (2-6C)alkanoylamino-(1-6C)alkyl or from a group of the formula :



wherein X⁷ is a direct bond or CO and Q⁵ is aryl, aryl-(1-6C)alkyl, heteroaryl,


heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl.

and wherein any CH₂ or CH₃ group within a R¹⁴ substituent optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino or from a group of the formula :




wherein X⁸ is a direct bond or is selected from O, N(R¹⁶), CON(R¹⁶), N(R¹⁶)CO and C(R¹⁶)₂O, wherein R¹⁶ is hydrogen or (1-6C)alkyl, and Q⁶ is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R¹⁵ optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylsulphonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl and (2-6C)alkanoyl, or optionally bears 1 substituent selected from a group of the formula :



wherein X⁹ is a direct bond or is selected from O and N(R¹⁸), wherein R¹⁸ is hydrogen or (1-6C)alkyl, and R¹⁷ is hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, and from a group of the formula :




wherein X¹⁰ is a direct bond or is selected from O, N(R¹⁹) and CO, wherein R¹⁹ is hydrogen or (1-6C)alkyl, and Q⁷ is heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R¹⁴ optionally bears 1 or 2 oxo substituents;


(u) R¹⁴ is selected from chloro, cyano, formyl, carboxy, carbamoyl, methoxycarbonyl, ethoxycarbonyl, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl, N,N-diethylcarbamoyl, acetyl, propionyl, chloromethyl, 2-chloroethyl, 3-chloropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl,

methoxymethyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, 2-cyanoethyl,
 3-cyanopropyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, methylaminomethyl,
 ethylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-ethylaminoethyl,
 3-ethylaminopropyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl,
 5 acetamidomethyl, 2-acetamidoethyl, 3-acetamidopropyl or from a group of the formula :



wherein X^7 is a direct bond or CO and Q^5 is phenyl, benzyl, 1-, 2- or 3-pyrrolidinyl,
 morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yl,
 piperidin-4-yl, 1-, 3- or 4-homopiperidinyl, piperazin-1-yl, homopiperazin-1-yl,
 10 1-, 2- or 3-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl,
 3- or 4-piperidinylmethyl, 1-, 3- or 4-homopiperidinylmethyl, 1,1-dioxotetrahydro-
 4H-1,4-thiazin-4-ylmethyl, piperazin-1-ylmethyl, homopiperazin-1-ylmethyl,
 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl,
 2-morpholinoethyl, 3-morpholinopropyl, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl,
 15 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl, 2-piperidinoethyl, 3-piperidinopropyl,
 2-piperidin-3-ylethyl, 3-piperidin-3-ylpropyl, 2-piperidin-4-ylethyl, 3-piperidin-4-ylpropyl,
 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl,
 3-piperazin-1-ylpropyl, 2-homopiperazin-1-ylethyl or 3-homopiperazin-1-ylpropyl,


and wherein any CH_2 or CH_3 group within a R^{14} substituent optionally bears on each
 20 said CH_2 or CH_3 group one or more fluoro, chloro or methyl groups or a substituent selected
 from hydroxy, amino, methoxy, methylsulphonyl, methylamino, dimethylamino,
 diisopropylamino, N-ethyl-N-methylamino, N-isopropyl-N-methylamino, N-methyl-
N-propylamino, acetoxy, acetamido and N-methylacetamido, or from a group of the formula :



25 wherein X^8 is a direct bond or is selected from O, NH, CONH, NHCO and CH_2O and Q^6 is
 pyridyl, pyridylmethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl,
 piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-
 2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl,
 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-
 30 3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-piperazin-1-ylethyl or 3-piperazin-
 1-ylpropyl,


and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^{14}
 optionally bears 1, 2 or 3 substituents which may be the same or different selected from

fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, allyl, 2-propynyl, methoxy, methylsulphonyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl and acetyl, or optionally bears 1 substituent selected from a group of the formula :



- 5 wherein X^9 is a direct bond or is selected from O and NH and R^{17} is 2-fluoroethyl, 3-fluoropropyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-ethylaminoethyl, 3-ethylaminopropyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, acetamidomethyl, methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl,

10 tert-butoxycarbonylaminomethyl and from a group of the formula :



wherein X^{10} is a direct bond or is selected from O, NH and CO and Q^7 is


- 15 2-morpholinoethyl, 3-morpholinopropyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, each of which optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy,

and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1 or 2

- 20 oxo substituents; and

(v) R^{14} is selected from cyano, formyl, carboxy, carbamoyl, methoxycarbonyl, ethoxycarbonyl, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl, N,N-diethylcarbamoyl, acetyl, propionyl, chloromethyl, 2-chloroethyl, 3-chloropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl,

- 25 methoxymethyl, 2-methoxyethyl, 3-methoxypropyl or from a group of the formula :




wherein X^7 is a direct bond or CO and Q^5 is 1-pyrrolidinyl, morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, 1-homopiperidinyl, piperazin-1-yl, homopiperazin-1-yl, 1-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 1-homopiperidinylmethyl,

- 30 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylmethyl, piperazin-1-ylmethyl, homopiperazin-1-ylmethyl or 3-morpholinopropyl,

and wherein any CH_2 or CH_3 group within a R^{14} substituent optionally bears on each said CH_2 or CH_3 group one or more fluoro, chloro or methyl groups or a substituent selected

from hydroxy, amino, methoxy, methylamino, dimethylamino, acetoxy, acetamido and N-methylacetamido,

and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from hydroxy, amino, carbamoyl, methyl, ethyl, allyl, 2-propynyl, methoxy, methylsulphonyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl and acetyl, or optionally bears 1 substituent selected from a group of the formula :



wherein X^9 is a direct bond and R^{17} is 2-fluoroethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, acetamidomethyl, methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl or tert-butoxycarbonylaminomethyl, and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1 or 2 oxo substituents.

A particular compound of the invention is a quinoline derivative of the Formula I wherein :

Z^1 is O or NH;

m is 1 and the R^1 group is located at the 5-, 6- or 7-position or m is 2 and each R^1 group, which may be the same or different, is located at the 5- and 7-positions or at the 6- and 7-positions and R^1 is selected from hydroxy, amino, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, pent-4-ynyloxy, hex-5-ynyloxy, methylamino, ethylamino, dimethylamino, diethylamino, acetamido, propionamido, 2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 4-pyrrolidin-1-ylbutoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy, piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy, 2-piperidin-3-ylethoxy, 3-piperidin-3-ylpropoxy, 2-piperidin-4-ylethoxy, 3-piperidin-4-ylpropoxy, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 4-piperazin-1-ylbutoxy, 2-homopiperazin-1-ylethoxy and 3-homopiperazin-1-ylpropoxy.

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R^1 substituent are optionally separated by the insertion into the chain of a group selected from O, NH, N(Me), CH=CH and C \equiv C,

and wherein any CH₂ or CH₃ group within a R^1 substituent optionally bears on each
5 said CH₂ or CH₃ group one or more fluoro or chloro groups or a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diethylamino, N-ethyl-N-methylamino, N-isopropyl-N-methylamino, N-methyl-N-propylamino and acetoxy;

and wherein any heteroaryl or heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro,
10 trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, methoxy, N-methylcarbamoyl and N,N-dimethylcarbamoyl and a pyrrolidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl or homopiperazin-1-yl group within a R^1 substituent is optionally N-substituted with allyl, methylsulphonyl, acetyl, 2-fluoroethyl, 3-fluoropropyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, 2-aminoethyl, 3-aminopropyl, 2-methylaminoethyl, 3-methylaminopropyl,
15 2-dimethylaminoethyl, 3-dimethylaminopropyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, the last 8 of which substituents each optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy,


20 and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 ~~oxo~~ substituents;

n is 0 or 1 and the R^3 group, if present, is located at the 5- or 6-position of the 1,3-benzodioxol-4-yl group and is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl, ethynyl, methoxy and ethoxy;

25 Z^2 is a C \equiv C or CH=CH group; and

R^{14} is selected from cyano, formyl, carboxy, carbamoyl, methoxycarbonyl, ethoxycarbonyl, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl, N,N-diethylcarbamoyl, acetyl, propionyl, chloromethyl, 2-chloroethyl, 3-chloropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl,
30 methoxymethyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, 2-cyanoethyl, 3-cyanopropyl, methylaminomethyl, ethylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-ethylaminoethyl, 3-ethylaminopropyl, dimethylaminomethyl,


2-dimethylaminoethyl, 3-dimethylaminopropyl, acetamidomethyl, 2-acetamidoethyl and 3-acetamidopropyl, or from a group of the formula :



wherein X^7 is a direct bond or CO and Q^5 is 1-pyrrolidinyl, morpholino, 1,1-dioxotetrahydro-
 5 4H-1,4-thiazin-4-yl, piperidino, 1-homopiperidinyl, piperazin-1-yl, homopiperazin-1-yl, 1-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 1-homopiperidinylmethyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylmethyl, piperazin-1-ylmethyl, homopiperazin-1-ylmethyl or 3-morpholinopropyl,

and wherein any CH_2 or CH_3 group within a R^{14} substituent optionally bears on each
 10 said CH_2 or CH_3 group one or more fluoro, chloro or methyl groups or a substituent selected from hydroxy, amino, methoxy, methylamino, dimethylamino, acetoxy, acetamido and N-methylacetamido,

and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1, 2 or
 3 substituents, which may be the same or different, selected from hydroxy, amino, carbamoyl,
 15 methyl, ethyl, allyl, 2-propynyl, methoxy, methylsulphonyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl and acetyl, or optionally bears 1 substituent selected from a group of the formula :



wherein X^9 is a direct bond and R^{17} is 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl,
 20 3-methoxypropyl, cyanomethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, acetamidomethyl, methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl or tert-butoxycarbonylaminomethyl,

and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1 or 2
 oxo substituents;

25 or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular compound of the invention is a quinoline derivative of the
 Formula I wherein :

Z^1 is NH;

m is 2 and the first R^1 group is a 6-methoxy group and the second R^1 group is located
 30 at the 7-position and is selected from methoxy, ethoxy, 2-fluoroethoxy, 2-chloroethoxy, 3-fluoropropoxy, 3-chloropropoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-(2-chloroethoxy)ethoxy, 2-(2-methoxyethoxy)ethoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy.

2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, 3-piperidin-3-ylpropoxy, 5 3-(N-methylpiperidin-3-yl)propoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-piperidin-4-ylpropoxy, 3-(N-methylpiperidin-4-yl)propoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(4-allylpiperazin-1-yl)propoxy, 3-(4-methylsulphonylpiperazin-1-yl)propoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy, 10 3-(4-cyanomethylpiperazin-1-yl)propoxy, 2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy, 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 2-(3-oxopiperazin-1-yl)ethoxy, 3-(3-oxopiperazin-1-yl)propoxy, 2-(2-pyrrolidin-1-ylethoxy)ethoxy, 2-(2-morpholinoethoxy)ethoxy, 2-(2-piperidinoethoxy)ethoxy and 2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy;

15 n is 0 or n is 1 and the R^3 group, if present, is located at the 5-position of the 1,3-benzodioxol-4-yl group and is selected from chloro and bromo; the $-Z^2-R^{14}$ group is located at the 7-position on the 1,3-benzodioxol-4-yl group, Z^2 is a $C\equiv C$ or $CH=CH$ group; and

R^{14} is selected from cyano, formyl, carboxy, carbamoyl, methoxycarbonyl, 20 ethoxycarbonyl, N-methylcarbamoyl, N-ethylcarbamoyl, N-(2-methoxyethyl)carbamoyl, N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl, N-(2-methoxyethyl)-N-methylcarbamoyl, acetyl, propionyl, chloromethyl, 2-chloroethyl, 3-chloropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, methoxymethyl, 2-methoxyethyl, 3-methoxypropyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, 25 1-pyrrolidinylcarbonyl, morpholinocarbonyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylcarbonyl, piperidinocarbonyl, piperazin-1-ylcarbonyl, 1-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylmethyl, piperazin-1-ylmethyl and 3-morpholinopropyl; or a pharmaceutically-acceptable acid-addition salt thereof.

30 A further particular compound of the invention is a quinoline derivative of the Formula I wherein :

Z^1 is NH;

- m is 2 and the first R¹ group is a 6-methoxy group and the second R¹ group is located at the 7-position and is selected from methoxy, ethoxy, 2-fluoroethoxy, 2-chloroethoxy, 3-fluoropropoxy, 3-chloropropoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-(2-chloroethoxy)ethoxy, 2-(2-methoxyethoxy)ethoxy, 2-pyrrolidin-1-ylethoxy, 5 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, 3-piperidin-3-ylpropoxy, 10 3-(N-methylpiperidin-3-yl)propoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-piperidin-4-ylpropoxy, 3-(N-methylpiperidin-4-yl)propoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(4-allylpiperazin-1-yl)propoxy, 3-(4-methylsulphonylpiperazin-1-yl)propoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy, 15 3-(4-cyanomethylpiperazin-1-yl)propoxy, 2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy, 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 2-(3-oxopiperazin-1-yl)ethoxy, 3-(3-oxopiperazin-1-yl)propoxy, 2-(2-pyrrolidin-1-ylethoxy)ethoxy, 2-(2-morpholinoethoxy)ethoxy, 2-(2-piperidinoethoxy)ethoxy and 2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy;
- 20 n is 0 or n is 1 and the R³ group, if present, is located at the 5-position of the 1,3-benzodioxol-4-yl group and is selected from chloro and bromo; the -Z²-R¹⁴ group is located at the 7-position on the 1,3-benzodioxol-4-yl group, Z² is a C≡C group; and R¹⁴ is selected from chloromethyl, 2-chloroethyl, 3-chloropropyl, hydroxymethyl, 25 2-hydroxyethyl, 3-hydroxypropyl, methoxymethyl, 2-methoxyethyl, 3-methoxypropyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, 1-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylmethyl, piperazin-1-ylmethyl and 3-morpholinopropyl; or a pharmaceutically-acceptable acid-addition salt thereof.
- 30 A further particular compound of the invention is a quinoline derivative of the Formula I wherein :
- Z¹ is NH:

- m is 2 and the first R¹ group is a 6-methoxy group and the second R¹ group is located at the 7-position and is selected from methoxy, ethoxy, 2-fluoroethoxy, 2-chloroethoxy, 3-fluoropropoxy, 3-chloropropoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-(2-chloroethoxy)ethoxy, 2-(2-methoxyethoxy)ethoxy, 2-pyrrolidin-1-ylethoxy,
- 5 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, 3-piperidin-3-ylpropoxy,
- 10 3-(N-methylpiperidin-3-yl)propoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-piperidin-4-ylpropoxy, 3-(N-methylpiperidin-4-yl)propoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(4-allylpiperazin-1-yl)propoxy, 3-(4-methylsulphonylpiperazin-1-yl)propoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy,
- 15 3-(4-cyanomethylpiperazin-1-yl)propoxy, 2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy, 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 2-(3-oxopiperazin-1-yl)ethoxy, 3-(3-oxopiperazin-1-yl)propoxy, 2-(2-pyrrolidin-1-ylethoxy)ethoxy, 2-(2-morpholinoethoxy)ethoxy, 2-(2-piperidinoethoxy)ethoxy and 2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy;
- 20 n is 0 or n is 1 and the R³ group, if present, is located at the 5-position of the 1,3-benzodioxol-4-yl group and is selected from chloro and bromo; the -Z²-R¹⁴ group is located at the 7-position on the 1,3-benzodioxol-4-yl group, Z² is a CH=CH group; and R¹⁴ is selected from cyano, formyl, carboxy, carbamoyl, methoxycarbonyl,
- 25 ethoxycarbonyl, N-methylcarbamoyl, N-ethylcarbamoyl, N-(2-methoxyethyl)carbamoyl, N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl, N-(2-methoxyethyl)-N-methylcarbamoyl, acetyl, propionyl, chloromethyl, 2-chloroethyl, 3-chloropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, methoxymethyl, 2-methoxyethyl, 3-methoxypropyl, dimethylaminomethyl, 2-dimethylaminoethyl,
- 30 3-dimethylaminopropyl, 1-pyrrolidinylcarbonyl, morpholinocarbonyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylcarbonyl, piperidinocarbonyl, piperazin-1-ylcarbonyl, 1-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylmethyl and piperazin-1-ylmethyl;

or a pharmaceutically-acceptable acid-addition salt thereof.

A further particular compound of the invention is a quinoline derivative of the Formula I wherein :

Z^1 is NH;

5 m is 2 and the first R^1 group is a 6-methoxy group and the second R^1 group is located at the 7-position and is selected from methoxy, ethoxy, 2-fluoroethoxy, 2-chloroethoxy, 3-fluoropropoxy, 3-chloropropoxy, 2-(2-chloroethoxy)ethoxy, 2-(2-methoxyethoxy)ethoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 10 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(4-allylpiperazin-1-yl)propoxy, 3-(4-methylsulphonylpiperazin-1-yl)propoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy, 3-(4-cyanomethylpiperazin-1-yl)propoxy, 2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy, 15 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 2-(3-oxopiperazin-1-yl)ethoxy, 3-(3-oxopiperazin-1-yl)propoxy and 2-(2-pyrrolidin-1-ylethoxy)ethoxy;

n is 0 or n is 1 and R^3 is a chloro group located at the 5-position of the 1,3-benzodioxol-4-yl group;

the $-Z^2-R^{14}$ group is located at the 7-position on the 1,3-benzodioxol-4-yl group,

20 Z^2 is a $C\equiv C$ group; and

R^{14} is selected from hydroxymethyl, methoxymethyl, dimethylaminomethyl, 1-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylmethyl and piperazin-1-ylmethyl;

or a pharmaceutically-acceptable acid-addition salt thereof.

25 A further particular compound of the invention is a quinoline derivative of the Formula I wherein :

Z^1 is NH;

m is 2 and the first R^1 group is a 6-methoxy group and the second R^1 group is located at the 7-position and is selected from methoxy, ethoxy, 2-fluoroethoxy, 2-chloroethoxy, 30 3-fluoropropoxy, 3-chloropropoxy, 2-(2-chloroethoxy)ethoxy, 2-(2-methoxyethoxy)ethoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,

- 3-piperidinopropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(4-allylpiperazin-1-yl)propoxy, 3-(4-methylsulphonylpiperazin-1-yl)propoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy, 3-(4-cyanomethylpiperazin-1-yl)propoxy, 2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy, 5 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 2-(3-oxopiperazin-1-yl)ethoxy, 3-(3-oxopiperazin-1-yl)propoxy and 2-(2-pyrrolidin-1-ylethoxy)ethoxy;

n is 0 or n is 1 and R³ is a chloro group located at the 5-position of the

1,3-benzodioxol-4-yl group;

the -Z²-R¹⁴ group is located at the 7-position on the 1,3-benzodioxol-4-yl group,

- 10 Z² is a CH=CH group; and

R¹⁴ is selected from cyano, carboxy, carbamoyl, methoxycarbonyl, ethoxycarbonyl,

N-methylcarbamoyl, N-ethylcarbamoyl, N-(2-methoxyethyl)carbamoyl,

N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl, N-(2-methoxyethyl)-

N-methylcarbamoyl, acetyl, propionyl, 1-pyrrolidinylcarbonyl, morpholinocarbonyl,


- 15 1,1-dioxotetrahydro-4H-1,4-thiazin-4-ylcarbonyl, piperidinocarbonyl and piperazin-1-ylcarbonyl;

or a pharmaceutically-acceptable acid-addition salt thereof.

Particular compounds of the invention include, for example, the quinoline derivatives of the Formula I described hereinafter in Examples 1, 2, 3, 9(1) to 9(7), 10 and 11.


- 20 A quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes, when used to prepare a quinoline derivative of the Formula I are provided as a further feature of the invention and are illustrated by the following representative process variants in which, unless otherwise stated, m, R¹, Z¹, n, R³, Z² and R¹⁴ 25 have any of the meanings defined hereinbefore. Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described in conjunction with the following representative process variants and within the accompanying Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic 30 chemist.

(a) For the production of those compounds of the Formula I wherein Z¹ is an O, S or N(R²) group, the reaction of a quinoline of the Formula II



II

wherein L is a displaceable group and m and R¹ have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with a compound of the Formula III



III

wherein Z¹ is O, S, or N(R²) and n, R³, R², Z² and R¹⁴ have any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any
10 protecting group that is present is removed by conventional means.

The reaction may conveniently be carried out in the presence of a suitable acid or in the presence of a suitable base. A suitable acid is, for example, an inorganic acid such as, for example, hydrogen chloride or hydrogen bromide. A suitable base is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine,
15 triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or, for example, an alkali or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide, or, for example, an alkali metal amide, for example sodium hexamethyldisilazane, or, for example, an alkali metal hydride, for example sodium hydride.

20 A suitable displaceable group L is, for example, a halogeno, alkoxy, aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, pentafluorophenoxy, methanesulphonyloxy or toluene-4-sulphonyloxy group. The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an alcohol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene
25 chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic solvent such as toluene, or a dipolar aprotic solvent such as

N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide. The reaction is conveniently carried out at a temperature in the range, for example, 0 to 250°C, preferably in the range 0 to 120°C.

Typically, the quinoline of the Formula II may be reacted with a compound of the
5 Formula III in the presence of an aprotic solvent such as N,N-dimethylformamide, conveniently in the presence of a base, for example potassium carbonate or sodium hexamethyldisilazane, and at a temperature in the range, for example, 0 to 150°C, preferably in the range, for example, 0 to 70°C.

The quinoline derivative of the Formula I may be obtained from this process in the
10 form of the free base or alternatively it may be obtained in the form of a salt with the acid of the formula H-L wherein L has the meaning defined hereinbefore. When it is desired to obtain the free base from the salt, the salt may be treated with a suitable base, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine,
4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or
15 diazabicyclo[5.4.0]undec-7-ene, or, for example, an alkali or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.

Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in
20 question and may be introduced by conventional methods. Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

25 Specific examples of protecting groups are given below for the sake of convenience, in which "lower", as in, for example, lower alkyl, signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection
30 not specifically mentioned are, of course, within the scope of the invention.

A carboxy protecting group may be the residue of an ester-forming aliphatic or arylaliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms). Examples of carboxy protecting groups include straight or

- branched chain (1-12C)alkyl groups (for example isopropyl, and tert-butyl);
lower alkoxy- lower alkyl groups (for example methoxymethyl, ethoxymethyl and
isobutoxymethyl); lower acyloxy-lower alkyl groups, (for example acetoxymethyl,
propionyloxymethyl, butyryloxymethyl and pivaloyloxymethyl); lower
5 alkoxycarbonyloxy-lower alkyl groups (for example 1-methoxycarbonyloxyethyl and
1-ethoxycarbonyloxyethyl); aryl-lower alkyl groups (for example benzyl, 4-methoxybenzyl,
2-nitrobenzyl, 4-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (for
example trimethylsilyl and tert-butyldimethylsilyl); tri(lower alkyl)silyl-lower alkyl groups
(for example trimethylsilylethyl); and (2-6C)alkenyl groups (for example allyl). Methods
10 particularly appropriate for the removal of carboxyl protecting groups include for example
acid-, base-, metal- or enzymically-catalysed cleavage.

- Examples of hydroxy protecting groups include lower alkyl groups (for example
tert-butyl), lower alkenyl groups (for example allyl); lower alkanoyl groups (for example
acetyl); lower alkoxycarbonyl groups (for example tert-butoxycarbonyl);
15 lower alkenyloxycarbonyl groups (for example allyloxycarbonyl); aryl-lower alkoxycarbonyl
groups (for example benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl,
2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl); tri(lower alkyl)silyl (for example
trimethylsilyl and tert-butyldimethylsilyl) and aryl-lower alkyl (for example benzyl) groups.


- Examples of amino protecting groups include formyl, aryl-lower alkyl groups (for
20 example benzyl and substituted benzyl, 4-methoxybenzyl, 2-nitrobenzyl and
2,4-dimethoxybenzyl, and triphenylmethyl); di-4-anisylmethyl and furylmethyl groups; lower
alkoxycarbonyl (for example tert-butoxycarbonyl); lower alkenyloxycarbonyl (for example
allyloxycarbonyl); aryl-lower alkoxycarbonyl groups (for example benzyloxycarbonyl,
4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl);
25 trialkylsilyl (for example trimethylsilyl and tert-butyldimethylsilyl); alkylidene (for example
methylidene) and benzyldiene and substituted benzyldiene groups.

- Methods appropriate for removal of hydroxy and amino protecting groups include, for
example, acid-, base-, metal- or enzymically-catalysed hydrolysis for groups such as
2-nitrobenzyloxycarbonyl, hydrogenation for groups such as benzyl and photolytically for
30 groups such as 2-nitrobenzyloxycarbonyl.

The reader is referred to Advanced Organic Chemistry, 4th Edition, by J. March,
published by John Wiley & Sons 1992. for general guidance on reaction conditions and

reagents and to Protective Groups in Organic Synthesis, 2nd Edition, by T. Green *et al.*, also published by John Wiley & Son, for general guidance on protecting groups.

Quinoline starting materials of the Formula II may be obtained by conventional procedures such as those disclosed in International Patent Applications WO 98/43960 and
 5 WO 00/68201. For example, a 1,4-dihydroquinolin-4-one of Formula IV



IV

wherein m and R¹ have any of the meanings defined hereinbefore except that any functional group is protected if necessary, may be reacted with a halogenating agent such as thionyl chloride, phosphoryl chloride or a mixture of carbon tetrachloride and triphenylphosphine
 10 whereafter any protecting group that is present is removed by conventional means.


The 4-chloroquinoline so obtained may be converted, if required, into a 4-pentafluorophenoxyquinoline by reaction with pentafluorophenol in the presence of a suitable base such as potassium carbonate and in the presence of a suitable solvent such as N,N-dimethylformamide.

15 2,3-Methylenedioxyanilino starting materials (Formula III, for example when Z is NH) may be obtained by conventional procedures as illustrated in the Examples. Corresponding 2,3-methylenedioxyphenol and 2,3-methylenedioxythiophenol starting materials (Formula III, when Z is O or S) may be obtained by conventional procedures.

(b) For the production of those compounds of the Formula I wherein at least one R¹ group
 20 is a group of the formula



wherein Q¹ is an aryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl-(1-6C)alkyl or heterocyclyl-(1-6C)alkyl group or an optionally substituted alkyl group and X¹ is an oxygen atom, the coupling, conveniently in the presence
 25 of a suitable dehydrating agent, of a quinoline of the Formula V



wherein m , R^1 , Z^1 , n , R^3 , Z^2 and R^{14} have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an appropriate alcohol of the formula Q^1-OH wherein any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means.

A suitable dehydrating agent is, for example, a carbodiimide reagent such as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or a mixture of an azo compound such as diethyl or di-tert-butyl azodicarboxylate and a phosphine such as triphenylphosphine. The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride and at a temperature in the range, for example, 10 to 150°C, preferably at or near ambient temperature.

The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride and at a temperature in the range, for example, 10 to 150°C, preferably at or near ambient temperature.

(c) For the production of those compounds of the Formula I wherein R^1 is an amino-substituted (1-6C)alkoxy group (such as 2-homopiperidin-1-ylethoxy or 3-dimethylaminopropoxy), the reaction of a compound of the Formula I wherein R^1 is a halogeno-substituted (1-6C)alkoxy group with a heterocyclyl compound or an appropriate amine. The reaction is conveniently carried out in the presence of a suitable inert diluent or carrier as defined hereinbefore and at a temperature in the range 10 to 150°C, preferably at or near ambient temperature.

(d) For the production of those compounds of the Formula I wherein an R^1 group contains a (1-6C)alkoxy or substituted (1-6C)alkoxy group or a (1-6C)alkylamino or substituted (1-6C)alkylamino group, the alkylation, conveniently in the presence of a suitable base as

defined hereinbefore, of a quinoline derivative of the Formula I wherein the R^1 group contains a hydroxy group or a primary or secondary amino group as appropriate.


A suitable alkylating agent is, for example, any agent known in the art for the alkylation of hydroxy to alkoxy or substituted alkoxy, or for the alkylation of amino to alkylamino or substituted alkylamino, for example an alkyl or substituted alkyl halide, for example a (1-6C)alkyl chloride, bromide or iodide or a substituted (1-6C)alkyl chloride, bromide or iodide, conveniently in the presence of a suitable base as defined hereinbefore, in a suitable inert solvent or diluent as defined hereinbefore and at a temperature in the range, for example, 10 to 140°C, conveniently at or near ambient temperature.

Conveniently for the production of those compounds of the Formula I wherein R^1 contains a (1-6C)alkylamino or substituted (1-6C)alkylamino group, a reductive amination reaction may be employed. For example, for the production of those compounds of the Formula I wherein R^1 contains a N-methyl group, the corresponding compound containing a N-H group may be reacted with formaldehyde in the presence of a suitable reducing agent. A suitable reducing agent is, for example, a hydride reducing agent, for example an alkali metal aluminium hydride such as lithium aluminium hydride or, preferably, an alkali metal borohydride such as sodium borohydride, sodium cyanoborohydride, sodium triethylborohydride, sodium trimethoxyborohydride and sodium triacetoxyborohydride. The reaction is conveniently performed in a suitable inert solvent or diluent, for example tetrahydrofuran and diethyl ether for the more powerful reducing agents such as lithium aluminium hydride, and, for example, methylene chloride or a protic solvent such as methanol and ethanol for the less powerful reducing agents such as sodium triacetoxyborohydride and sodium cyanoborohydride. The reaction is performed at a temperature in the range, for example, 10 to 80°C, conveniently at or near ambient temperature.

(e) For the production of those compounds of the Formula I wherein Z^1 is a SO or SO₂ group, wherein an R^1 or R^3 substituent is a (1-6C)alkylsulphinyl or (1-6C)alkylsulphonyl group or wherein an R^1 , R^3 or R^{14} substituent contains a SO or SO₂ group, the oxidation of a compound of Formula I wherein Z^1 is a S group or wherein an R^1 or R^3 substituent is a (1-6C)alkylthio group or wherein an R^1 , R^3 or R^{14} substituent contains a S group as appropriate.

Conventional oxidation reagents and reaction conditions for such partial or complete oxidation of a sulphur atom are well known to the organic chemist.

(f) The reaction, conveniently in the presence of a suitable base as defined hereinbefore and in the presence of a suitable catalyst, of a compound of the Formula VI



wherein L is a displaceable group as defined hereinbefore and m, R¹, Z¹, n and R³ have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with a compound of the Formula VII



wherein Z² is a C≡C or C(R¹³)=C(R¹³) group and R¹³ and R¹⁴ have any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed by conventional means.

Conveniently the displaceable group is a halogeno group such as iodo, bromo or chloro. A suitable catalyst is, for example, an organometallic reagent, for example an organopalladium compound such as tetrakis(triphenylphosphine)palladium(0) or bis(triphenylphosphine)palladium(II) dichloride. The conversion reaction is conveniently carried out in the presence of a suitable inert diluent or carrier as defined hereinbefore and at a temperature in the range 10 to 150°C, preferably at or near 60°C.

(g) For the production of a compound of the Formula I wherein R¹⁴ is a carboxy group, the cleavage of a compound of the Formula I wherein R¹⁴ is a (1-6C)alkoxycarbonyl group.

The cleavage reaction is conveniently carried out by the hydrolysis of the (1-6C)alkoxycarbonyl group in the presence of a suitable base, for example an alkali or alkaline earth metal carbonate or hydroxide such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide and in the presence of a suitable inert diluent or carrier as defined hereinbefore such as methanol and at a temperature in the range 10 to 150°C, preferably at or near 40°C.

(h) The reaction, conveniently in the presence of a suitable dehydrating agent as defined hereinbefore, of a compound of the Formula I wherein R¹³ is a carboxy group with an---

appropriate amine to form a further compound of the Formula I wherein R^{14} is a carbamoyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl or heterocyclylcarbonylamino group.

The reaction is conveniently carried out in the presence of a suitable inert diluent or carrier as defined hereinbefore and at a temperature in the range, for example, 10 to 150°C, preferably at or near ambient temperature.

When a pharmaceutically-acceptable salt of a quinoline derivative of the Formula I is required, for example an acid-addition salt, it may be obtained by, for example, reaction of said quinoline derivative with a suitable acid using a conventional procedure.

10 Biological Assays

The following assays can be used to measure the effects of the compounds as inhibitors of the MAPK pathway.

(a) Assay to detect MEK inhibition

To evaluate inhibitors of the MAPK pathway, a coupled assay was carried out which measures phosphorylation of serine/threonine residues present in the substrate in the presence or absence of inhibitor. Recombinant glutathione S-transferase fusion protein containing human p45MEK1 (GST-MEK) was activated by c-raf (Sf9 insect cell lysate from triple baculoviral infection with c-raf/ras/lck) and used for the assay. Active GST-MEK was first used to activate a recombinant glutathione S-transferase fusion protein containing p44MAP kinase (GST-MAPK) in the presence of ATP and Mg^{2+} for 60 minutes at room temperature in the presence or absence of potential inhibitors. The activated GST-MAPK was then incubated with myelin basic protein (MBP) as substrate for 10 minutes at room temperature in the presence of ATP, Mg^{2+} and ^{33}P -ATP. The reaction was stopped by addition of 20% v/v phosphoric acid. Incorporation of ^{33}P into the myelin basic protein was determined by capture of the substrate on a filter mat, washing and counting using scintillation methods. The extent of inhibition was determined by comparison with untreated controls.

The final assay solution contained 10mM Tris, pH 7.5, 0.05mM EGTA, 8.33 μ M [γ - ^{33}P]ATP, 8.33mM $Mg(OAc)_2$, 0.5mM sodium orthovanadate, 0.05%w/v BSA, 6.5ng GST-MEK, 1 μ g GST-MAPK and 16.5 μ g MBP in a reaction volume of 60 μ l.

30 (b) In vitro MAP kinase assay

To determine whether compounds were inhibiting GST-MEK or GST-MAPK, a direct assay of MAPK activity was employed. GST-MAPK was activated by a constitutively active

.. GST-MEK fusion protein containing two point mutations (S217E, S221E) and used for the assay in the presence and absence of potential inhibitors. The activated GST-MAPK was incubated with substrate (MBP) for 60min at room temperature in the presence of ATP, Mg^{2+} and ^{33}P -ATP. The reaction was stopped by addition of 20% v/v phosphoric acid.

- 5 Incorporation of ^{33}P into the myelin basic protein was determined by capture of the substrate on a filter mat, washing and counting using scintillation methods.

The final assay solution contained 12mM Tris, pH 7.5, 0.06mM EGTA, 30 μ M [γ ^{33}P]ATP, 10mM $Mg(OAc)_2$, 0.6mM sodium orthovanadate, 0.06%w/v BSA, 28ng GST-MAPK and 16.5 μ g MBP in a reaction volume of 60 μ l.

10 (c) Cell proliferation assays

Cells were seeded into multi-well plates at 20,000 - 40,000 cells/ml in growth medium containing 5% FCS and incubated overnight at 37°C. The compounds were prepared in fresh medium at an appropriate concentration and added to the wells containing the cells. These were then incubated for a further 72 hours. Cells were then either removed from the wells by
15 incubating with trypsin/EDTA and counted using a Coulter counter, or treated with XTT/PMS in PBSA and optical densities read at 450nm.

The following assays can be used to measure the effects of the compounds of the present invention as c-Src tyrosine kinase inhibitors, as inhibitors in vitro of the proliferation of c-Src transfected fibroblast cells, as inhibitors in vitro of the migration of A549 human lung
20 tumour cells and as inhibitors in vivo of the growth in nude mice of xenografts of A549 tissue.

(d) In Vitro Src Enzyme Assay

The ability of test compounds to inhibit the phosphorylation of a tyrosine containing polypeptide substrate by the enzyme c-Src kinase was assessed using a conventional Elisa assay.

- 25 A substrate solution [100 μ l of a 20 μ g/ml solution of the polyamino acid Poly(Glu, Tyr) 4:1 (Sigma Catalogue No. P0275) in phosphate buffered saline (PBS) containing 0.2mg/ml of sodium azide] was added to each well of a number of Nunc 96-well immunoplates (Catalogue No. 439454) and the plates were sealed and stored at 4°C for 16 hours. The excess of substrate solution was discarded, and aliquots of Bovine Serum
30 Albumin (BSA; 150 μ l of a 5% solution in PBS) were transferred into each substrate-coated assay well and incubated for 1 hour at ambient temperature to block non specific binding. The

assay plate wells were washed in turn with PBS containing 0.05% v/v Tween 20 (PBST) and with Hepes pH7.4 buffer (50mM, 300µl/well) before being blotted dry.

Each test compound was dissolved in dimethyl sulphoxide and diluted with distilled water to give a series of dilutions (from 100µM to 0.001µM). Portions (25µl) of each dilution of test compound were transferred to wells in the washed assay plates. "Total" control wells contained diluted DMSO instead of compound. Aliquots (25µl) of an aqueous magnesium chloride solution (80mM) containing adenosine-5'-triphosphate (ATP; 40µM) was added to all test wells except the "blank" control wells which contained magnesium chloride without ATP.

Active human c-Src kinase (recombinant enzyme expressed in Sf9 insect cells; obtained from Upstate Biotechnology Inc. product 14-117) was diluted immediately prior to use by a factor of 1:10,000 with an enzyme diluent which comprised 100mM Hepes pH7.4 buffer, 0.2mM sodium orthovanadate, 2mM dithiothreitol and 0.02% BSA. To start the reactions, aliquots (50µl) of freshly diluted enzyme were added to each well and the plates were incubated at ambient temperature for 20 minutes. The supernatant liquid in each well was discarded and the wells were washed twice with PBST. Mouse IgG anti-phosphotyrosine antibody (Upstate Biotechnology Inc. product 05-321; 100µl) was diluted by a factor of 1:6000 with PBST containing 0.5% w/v BSA and added to each well. The plates were incubated for 1 hour at ambient temperature. The supernatant liquid was discarded and each well was washed with PBST (x4). Horse radish peroxidase (HRP)-linked sheep anti-mouse Ig antibody (Amersham Catalogue No. NXA 931; 100µl) was diluted by a factor of 1:500 with PBST containing 0.5% w/v BSA and added to each well. The plates were incubated for 1 hour at ambient temperature. The supernatant liquid was discarded and the wells were washed with PBST (x4).

A PCSB capsule (Sigma Catalogue No. P4922) was dissolved in distilled water (100ml) to provide phosphate-citrate pH5 buffer (50mM) containing 0.03% sodium perborate. An aliquot (50ml) of this buffer was mixed with a 50mg tablet of 2,2'-azinobis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS; Boehringer Catalogue No. 1204 521). Aliquots (100µl) of the resultant solution were added to each well. The plates were incubated for 20 to 60 minutes at ambient temperature until the optical density value of the "total" control wells, measured at 405nm using a plate reading spectrophotometer, was

approximately 1.0. "Blank" (no ATP) and "total" (no compound) control values were used to determine the dilution range of test compound which gave 50% inhibition of enzyme activity.

(e) In Vitro c-Src transfected NIH 3T3 (c-src 3T3) Fibroblast Proliferation Assay

This assay determined the ability of a test compound to inhibit the proliferation of
5 National Institute of Health (NIH) mouse 3T3 fibroblast cells that had been stably-transfected with an activating mutant (Y530F) of human c-Src.

Using a similar procedure to that described by Shalloway *et al.*, Cell, 1987, 49, 65-73, NIH 3T3 cells were transfected with an activating mutant (Y530F) of human c-Src. The resultant c-Src 3T3 cells were typically seeded at 1.5×10^4 cells per well into 96-well tissue-
10 culture-treated clear assay plates (Costar) each containing an assay medium comprising Dulbecco's modified Eagle's medium (DMEM; Sigma) plus 0.5% foetal calf serum (FCS), 2mM glutamine, 100 units/ml penicillin and 0.1mg/ml streptomycin in 0.9% aqueous sodium chloride solution. The plates were incubated overnight at 37°C in a humidified (7.5% CO₂ : 95% air) incubator.

15 Test compounds were solubilised in DMSO to form a 10mM stock solution. Aliquots of the stock solution were diluted with the DMEM medium described above and added to appropriate wells. Serial dilutions were made to give a range of test concentrations. Control wells to which test compound was not added were included on each plate. The plates were incubated overnight at 37°C in a humidified (7.5% CO₂ : 95% air) incubator.

20 BrdU labelling reagent (Boehringer Mannheim Catalogue No. 647 229) was diluted by a factor of 1:100 in DMEM medium containing 0.5% FCS and aliquots (20µl) were added to each well to give a final concentration of 10µM. The plates were incubated at 37°C for 2 hours. The medium was decanted. A denaturing solution (FixDenat solution, Boehringer Mannheim Catalogue No. 647 229; 50µl) was added to each well and the plates were placed
25 on a plate shaker at ambient temperature for 45 minutes. The supernatant was decanted and the wells were washed with PBS (200µl per well). Anti-BrdU-Peroxidase solution (Boehringer Mannheim Catalogue No. 647 229) was diluted by a factor of 1:100 in PBS containing 1% BSA and 0.025% dried skimmed milk (Marvel (registered trade mark), Premier Beverages, Stafford, GB) and an aliquot (100µl) of the resultant solution was added to each
30 well. The plates were placed on a plate shaker at ambient temperature for 90 minutes. The wells were washed with PBS (x5) to ensure removal of non-bound antibody conjugate. The plates were blotted dry and tetramethylbenzidine substrate solution (Boehringer Mannheim

Catalogue No. 647 229; 100 μ l) was added to each well. The plates were gently agitated on a plate shaker while the colour developed during a 10 to 20 minute period. The absorbance of the wells was measured at 690nm. The extent of inhibition of cellular proliferation at a range of concentrations of each test compound was determined and an anti-proliferative IC₅₀ value was derived.

(f) In Vitro Microdroplet Migration Assay

This assay determines the ability of a test compound to inhibit the migration of adherent mammalian cell lines, for example the human tumour cell line A549.

RPMI medium(Sigma) containing 10% FCS, 1% L-glutamine and 0.3% agarose (Difco Catalogue No. 0142-01) was warmed to 37°C in a water bath. A stock 2% aqueous agar solution was autoclaved and stored at 42°C. An aliquot (1.5 ml) of the agar solution was added to RPMI medium (10 ml) immediately prior to its use. A549 cells (Accession No. ATCC CCL185) were suspended at a concentration of 2×10^7 cells/ml in the medium and maintained at a temperature of 37°C.

A droplet (2 μ l) of the cell/agarose mixture was transferred by pipette into the centre of each well of a number of 96-well, flat bottomed non-tissue-culture-treated microtitre plate (Bibby Sterilin Catalogue No. 642000). The plates were placed briefly on ice to speed the gelling of the agarose-containing droplets. Aliquots (90 μ l) of medium which had been cooled to 4°C were transferred into each well, taking care not to disturb the microdroplets. Test compounds were diluted from a 10mM stock solution in DMSO using RPMI medium as described above. Aliquots (10 μ l) of the diluted test compounds were transferred to the wells, again taking care not to disturb the microdroplets. The plates were incubated at 37°C in a humidified (7.5% CO₂ : 95% air) incubator for about 48 hours.

Migration was assessed visually and the distance of migration was measured back to the edge of the agar droplet. A migratory inhibitory IC₅₀ was derived by plotting the mean migration measurement against test compound concentration.

(g) In Vivo A549 Xenograft Growth Assay

This test measures the ability of compounds to inhibit the growth of the A549 human carcinoma grown as a tumour in athymic nude mice (Alderley Park nu/nu strain). A total of about 5×10^6 A549 cells in matrigel (Beckton Dickinson Catalogue No. 40234) were injected subcutaneously into the left flank of each test mouse and the resultant tumours were allowed to grow for about 14 days. Tumour size was measured twice weekly using callipers and a

theoretical volume was calculated. Animals were selected to provide control and treatment groups of approximately equal average tumour volume. Test compounds were prepared as a ball-milled suspension in 1% polysorbate vehicle and dosed orally once daily for a period of about 28 days. The effect on tumour growth was assessed.

5 Although the pharmacological properties of the compounds of the Formula I vary with structural change as expected, in general activity possessed by compounds of the Formula I, may be demonstrated at the following concentrations or doses in one or more of the above tests (a) to (g) :-

- | | | |
|----|------------|---|
| | Test (a):- | IC ₅₀ in the range, for example, less than 4 μ M; |
| 10 | Test (b):- | activity was observed in this screen; |
| | Test (c):- | IC ₅₀ in the range, for example, less than 30 μ M. |
| | Test (d):- | IC ₅₀ in the range, for example, 0.001 - 10 μ M; |
| | Test (d):- | IC ₅₀ in the range, for example, 0.01 - 20 μ M; |
| | Test (f):- | activity in the range, for example, 0.1-25 μ M; |
| 15 | Test (g):- | activity in the range, for example, 1-200 mg/kg/day; |

No physiologically-unacceptable toxicity was observed in Test (g) at the effective dose for compounds tested of the present invention. Accordingly no untoward toxicological effects are expected when a compound of Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore is administered at the dosage ranges defined hereinafter.

20 According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

The compositions of the invention may be in a form suitable for oral use (for example
25 as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile
30 aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the invention may be obtained by conventional procedures using

conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

5 The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98
10 percent by weight of the total composition.

The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.

15 In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.1 mg/kg to 75 mg/kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.1 mg/kg to 30 mg/kg body weight will
20 generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg/kg to 25 mg/kg body weight will be used. Oral administration is however preferred, particularly in tablet form. Typically, unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of this invention.

According to a further aspect of the invention there is provided a quinoline derivative
25 of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.

As stated above we have also found that the quinoline derivatives of the present invention of Formula I possess potent anti-tumour activity which it is believed is obtained by way of inhibition of one or more of the MEK enzymes that are involved in the MAPK
30 pathway.

Accordingly, the quinoline derivatives of Formula I are of value as anti-proliferative agents in the containment and/or treatment of solid tumour disease. Particularly, the compounds of Formula I are expected to be useful in the prevention or treatment of those

tumours which are sensitive to inhibition of one or more of the MEK enzymes that are involved in the MAPK pathway. Further, the compounds of Formula I are expected to be useful in the prevention or treatment of those tumours which are mediated alone or in part by inhibition of the MEK enzymes *i.e.* the compounds may be used to produce a MEK enzyme inhibitory effect in a warm-blooded animal in need of such treatment. Specifically, the compounds of Formula I are expected to be useful in the prevention or treatment of solid tumour disease.

Thus, according to this aspect of the invention there is provided of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

According to a further aspect of the invention there is provided the use of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

According to a further feature of the invention there is provided a method for producing an anti-proliferative effect by the containment and/or treatment of solid tumour disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

According to a further aspect of the invention there is provided the use of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the prevention or treatment of solid tumour disease in a warm-blooded animals such as man.

According to a further feature of this aspect of the invention there is provided a method for the prevention or treatment of solid tumour disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

According to a further aspect of the invention there is provided the use of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the prevention or treatment of tumours which are sensitive to inhibition of MEK enzymes that are involved in the

MAPK pathway. Particular enzymes that the tumours may be sensitive to are MEK 1, MEK 2 and MEK 5.

According to a further feature of this aspect of the invention there is provided a method for the prevention or treatment of those tumours which are sensitive to inhibition of
5 MEK enzymes that are involved in the MAPK pathway which comprises administering to said animal an effective amount of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

According to a further aspect of the invention there is provided the use of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined
10 hereinbefore in the manufacture of a medicament for use in providing a MEK enzyme inhibitory effect.

According to a further feature of this aspect of the invention there is provided a method for providing a MEK enzyme inhibitory effect which comprises administering to said animal an effective amount of a quinoline derivative of the Formula I, or a
15 pharmaceutically-acceptable salt thereof, as defined hereinbefore.

We have also found that the quinoline derivatives of the present invention possess potent anti-tumour activity which it is believed is obtained by way of inhibition of one or more of the non-receptor tyrosine-specific protein kinases such as c-Src kinase that are involved in the signal transduction steps which lead to the invasiveness and migratory ability.
20 of metastasising tumour cells.

Particularly, the quinoline derivatives of the present invention are of value as anti-invasive agents in the containment and/or treatment of solid tumour disease. Particularly, the compounds of the present invention are expected to be useful in the prevention or treatment of those tumours which are sensitive to inhibition of one or more of the multiple non-receptor
25 tyrosine kinases such as c-Src kinase that are involved in the signal transduction steps which lead to the invasiveness and migratory ability of metastasising tumour cells. Further, the compounds of the present invention are expected to be useful in the prevention or treatment of those tumours which are mediated alone or in part by inhibition of the enzyme c-Src, i.e. the compounds may be used to produce a c-Src enzyme inhibitory effect in a warm-blooded
30 animal in need of such treatment. Specifically, the compounds of the present invention are expected to be useful in the prevention or treatment of solid tumour disease.

According to this aspect of the invention there is provided a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

According to a further feature of this aspect of the invention there is provided the use
5 of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

According to a further feature of this aspect of the invention there is provided a method for producing an anti-invasive effect by the containment and/or treatment of solid
10 tumour disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

According to a further aspect of the invention there is provided the use of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined
15 hereinbefore in the manufacture of a medicament for use in the prevention or treatment of those tumours which are sensitive to inhibition of non-receptor tyrosine kinases such as c-Src kinase that are involved in the signal transduction steps which lead to the invasiveness and migratory ability of metastasising tumour cells.

According to a further feature of this aspect of the invention there is provided a
20 method for the prevention or treatment of those tumours which are sensitive to inhibition of non-receptor tyrosine kinases such as c-Src kinase that are involved in the signal transduction steps which lead to the invasiveness and migratory ability of metastasising tumour cells which comprises administering to said animal an effective amount of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

25 According to a further aspect of the invention there is provided the use of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in providing a c-Src kinase inhibitory effect.

According to a further feature of this aspect of the invention there is provided a
30 method for providing a c-Src kinase inhibitory effect which comprises administering to said animal an effective amount of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

The anti-proliferative and anti-invasive treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the quinoline derivative of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents :-

- 5 (i) other anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
- (ii) other anti-proliferative or antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas);
- 10 antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred antimetabolites disclosed in European Patent Application No. 562734 such as (2S)-2-{o-fluoro-p-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl]-N-(prop-2-ynyl)amino]benzamido}-4-(tetrazol-5-yl)butyric acid); antitumour antibiotics (for
- 15 example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);
- 20 (iii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifyfene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5
- 25 α -reductase such as finasteride;
- (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies, farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example the EGFR tyrosine kinase inhibitors N-(3-chloro-4-
- 30 fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (ZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (CP 358774) and 6-acrylamido-N-(3-chloro-4-

fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;

- (v) antiangiogenic agents such as those which inhibit vascular endothelial growth factor
5 such as the compounds disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354 and those that work by other mechanisms (for example linomide, inhibitors of integrin $\alpha v \beta 3$ function and angiostatin);
- (vi) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;
- 10 (vii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and
- 15 (viii) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines
20 and approaches using anti-idiotypic antibodies.

According to this aspect of the invention there is provided a pharmaceutical product comprising a quinoline derivative of the formula I as defined hereinbefore and an additional anti-tumour agent as defined hereinbefore for the conjoint treatment of cancer.

Although the compounds of the Formula I are primarily of value as therapeutic agents
25 for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit the effects of the MEK enzymes that are involved in the MAPK kinase pathway or the effects of c Src. Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.

The invention will now be illustrated in the following Examples in which, generally :

- 30 (i) operations were carried out at ambient temperature, *i.e.* in the range 17 to 25°C and under an atmosphere of an inert gas such as argon unless otherwise stated;

(ii) evaporations were carried out by rotary evaporation *in vacuo* and work-up procedures were carried out after removal of residual solids by filtration;

(iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany or high pressure liquid chromatography (HPLC) was performed on C18 reverse phase silica, for example on a Dynamax C-18 60Å preparative reversed-phase column;

(iv) yields, where present, are not necessarily the maximum attainable;

(v) in general, the end-products of the Formula I have satisfactory microanalyses and their structures were confirmed by nuclear magnetic resonance (NMR) and/or mass spectral techniques; fast-atom bombardment (FAB) mass spectral data were obtained using a Platform spectrometer and, where appropriate, either positive ion data or negative ion data were collected; NMR chemical shift values were measured on the delta scale [proton magnetic resonance spectra were determined using a Jeol JNM EX 400 spectrometer operating at a field strength of 400MHz, Varian Gemini 2000 spectrometer operating at a field strength of 300MHz or a Bruker AM300 spectrometer operating at a field strength of 300MHz]; the following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad;

(vi) intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, HPLC, infra-red (IR) and/or NMR analysis;

(vii) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus or an oil-bath apparatus; melting points for the end-products of the Formula I were determined after crystallisation from a conventional organic solvent such as ethanol, methanol, acetone, ether or hexane, alone or in admixture;

(viii) the following abbreviations have been used:-

| | |
|------|-------------------------------|
| DMF | <u>N,N</u> -dimethylformamide |
| DMSO | dimethylsulphoxide |
| THF | tetrahydrofuran |

Example 1**3-cyano-6,7-dimethoxy-4-[4-(3-methoxyprop-1-ynyl)-
2,3-methylenedioxyanilino]quinoline monohydrochloride salt**

A mixture of 3-cyano-4-(4-iodo-2,3-methylenedioxyanilino)-6,7-dimethoxyquinoline
5 (0.2 g), methyl 2-propynyl ether (0.071 ml), tetrakis(triphenylphosphine)palladium(0)
(0.05 g), cuprous iodide (0.01 g) and N,N-diethylamine (4 ml) was stirred and heated to 60°C
for 4 hours. The reaction mixture was evaporated and the residue was partitioned between
methylene chloride and a 2N aqueous hydrochloric acid solution. The precipitate that was
formed was isolated by filtration, washed in turn with methylene chloride, ethanol and diethyl
10 ether and dried. There was thus obtained the title compound (0.085 g); NMR Spectrum:
(DMSO-d₆) 3.33 (s, 3H), 3.98 (s, 3H), 3.99 (s, 3H), 4.36 (s, 2H), 6.12 (s, 2H), 6.98 (d, 1H),
7.02 (d, 1H), 7.47 (s, 1H), 8.13 (s, 1H), 8.98 (s, 1H); Mass Spectrum: M+H⁺ 418.

The 3-cyano-4-(4-iodo-2,3-methylenedioxyanilino)-6,7-dimethoxyquinoline used as a
starting material was prepared as follows :-

15 Sodium hexamethyldisilazane (1M solution in THF; 3.8 ml) was added to a solution of
4-iodo-2,3-methylenedioxyaniline (0.5 g) in DMF (12 ml) that was cooled to 0°C and the
mixture was stirred for 5 minutes. A solution of 4-chloro-3-cyano-6,7-dimethoxyquinoline
(International Patent Application WO 98/43960; 0.43 g) in DMF (3 ml) was added and the
resultant mixture was stirred at ambient temperature for 2 hours. The reaction mixture was
20 diluted with water and extracted with ethyl acetate. The organic phase was washed with water
and with a saturated brine solution, dried over magnesium sulphate and evaporated. The
residue was purified by column chromatography on silica increasingly polar mixtures of
methylene chloride and ethyl acetate as eluent. There was thus obtained 3-cyano-4-(4-iodo-
2,3-methylenedioxyanilino)-6,7-dimethoxyquinoline as a solid (0.8 g); NMR Spectrum:
25 (DMSO-d₆) 3.77 (s, 3H), 3.81 (s, 3H), 5.88 (s, 2H), 6.3 (d, 1H), 6.87 (d, 1H), 6.93 (s, 1H), 7.7
(s, 1H), 7.83 (s, 1H); Mass Spectrum: M+H⁺ 476.

The 4-iodo-2,3-methylenedioxyaniline used as a starting material was prepared as
follows :-

A mixture of 2,3-dihydroxybenzoic acid (5 g), methanol (50 ml) and concentrated
30 sulphuric acid (10 drops) was stirred and heated to 60°C for 24 hours. The mixture was
evaporated and the residue was taken up in ethyl acetate. The organic solution was washed
with a saturated solution of sodium bicarbonate, dried over magnesium sulphate and

evaporated to give methyl 2,3-dihydroxybenzoate (2.19 g); NMR Spectrum: (CDCl_3) 3.95 (s, 3H), 5.7 (s, 1H), 6.8 (t, 1H), 7.15 (d, H), 7.35 (d, H).

After repetition of the previous reaction, a mixture of methyl 2,3-dihydroxybenzoate (2.8 g), potassium fluoride (4.8 g) and DMF (45 ml) was stirred at ambient temperature for 5 30 minutes. Dibromomethane (1.28 ml) was added and the mixture was heated to 120°C for 3 hours. The mixture was cooled to ambient temperature, poured into water and extracted with diethyl ether. The organic phase was washed with water and with a saturated brine solution, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography using a 9:1 mixture of petroleum ether (b.p. $40-60^\circ\text{C}$) and ethyl acetate as 10 eluent. There was thus obtained methyl 2,3-methylenedioxybenzoate (2.3 g) as a solid; NMR Spectrum: (CDCl_3) 3.95 (s, 3H), 6.1 (s, 2H), 6.85 (t, 1H), 7.0 (d, 1H), 7.45 (d, 1H).

A mixture of the material so obtained, a 2N aqueous potassium hydroxide solution (15.5 ml) and methanol (40 ml) was stirred at ambient temperature for 2 hours. The solution was concentrated to about one quarter of the original volume and cooled in an ice bath. The 15 mixture was acidified to pH3.5 by the addition of a 2N aqueous hydrochloric acid solution. The resultant precipitate was collected by filtration and washed in turn with water and diethyl ether. There was thus obtained 2,3-methylenedioxybenzoic acid (1.87 g); NMR Spectrum: (DMSO-d_6) 6.1 (s, 1H), 6.9 (t, 1H), 7.15 (d, 1H), 7.3 (d, 1H), 13.0 (br s, 1H).

The material so obtained was suspended in anhydrous dioxane (30 ml) and anhydrous 20 diphenylphosphoryl azide (2.45 ml), triethylamine (1.6 ml) and tert-butanol (9 ml) were added. The mixture was heated to reflux for 5 hours. The mixture was cooled to ambient temperature, concentrated by evaporation and diluted with ethyl acetate. The organic phase was washed in turn with a 5% aqueous citric acid solution, water, an aqueous sodium bicarbonate solution and a saturated brine solution and dried over magnesium sulphate. The 25 solvent was evaporated and the residue was purified by column chromatography on silica using a 19:1 mixture of petroleum ether (b.p. $40-60^\circ\text{C}$) and ethyl acetate as eluent. There was thus obtained tert-butyl N-(2,3-methylenedioxyphenyl)carbamate (1.98 g) as a solid; NMR Spectrum: (CDCl_3) 1.55 (s, 9H), 5.95 (s, 2H), 6.4 (br s, 1H), 6.55 (d, 1H), 6.8 (t, 1H), 7.45 (d, 1H).

30 A 5N aqueous hydrochloric acid solution (30 ml) was added to a solution of tert-butyl N-(2,3-methylenedioxyphenyl)carbamate (1.9 g) in ethanol (38 ml) and the reaction mixture was stirred at ambient temperature for 20 hours. The ethanol was evaporated and the residual aqueous phase was washed with diethyl ether and neutralised to pH7 by the addition of solid

potassium hydroxide. The resultant mixture was filtered and the aqueous phase was extracted with diethyl ether. The organic phase was washed with a saturated brine solution, dried over magnesium sulphate and evaporated. There was thus obtained 2,3-methylenedioxyaniline (1.0 g) as an oil; NMR Spectrum: (CDCl₃) 3.0 (br s, 2H), 5.9 (s, 2H), 6.3 (m, 2H), 7.25 (t, 5 1H).

Benzyltrimethylammonium dichloroiodate (2.8 g) was added portionwise during 10 minutes to a stirred mixture of 2,3-methylenedioxyaniline (1 g), calcium carbonate (0.95 g), methanol (5 ml) and methylene chloride (10 ml). The reaction mixture was stirred at ambient temperature for 1.5 hours. The resultant mixture was diluted with water and 10 extracted with methylene chloride. The organic phase was washed with water and with a saturated brine solution, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of isohexane and methylene chloride as eluent. There was thus obtained 4-iodo-2,3-methylenedioxyaniline as a solid (1.1 g); NMR Spectrum: (DMSO-d₆) 5.04 (br s, 2H), 5.94 (s, 2H), 6.13 (d, 1H), 6.8 15 (d, 1H).

Example 2

3-cyano-6,7-dimethoxy-4-[6-chloro-4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline

20 A mixture of 4-(6-chloro-4-iodo-2,3-methylenedioxyanilino)-3-cyano-6,7-dimethoxyquinoline (0.25 g), methyl 2-propynyl ether (0.09 ml), N,N-diisopropylamine (0.154 ml), bis(triphenylphosphine)palladium(II) dichloride (0.069 g), cuprous iodide (0.028 g) and ethyl acetate (10 ml) was stirred and heated to reflux for 12 hours. The reaction mixture was cooled to ambient temperature and partitioned between ethyl acetate and water. 25 The organic layer was dried over magnesium sulphate and evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of hexane and ethyl acetate as eluent. There was thus obtained the title compound as an oil (0.138 g); NMR Spectrum: (DMSO-d₆) 3.42 (s, 3H), 3.97 (s, 3H), 3.99 (s, 3H), 4.38 (s, 2H), 6.17 (s, 2H), 7.13 (s, 1H), 7.36 (s, 1H), 7.92 (s, 1H), 8.39 (s, 1H), 9.42 (br s, 1H); Mass Spectrum: M+H⁺ 452.

30 The 4-(6-chloro-4-iodo-2,3-methylenedioxyanilino)-3-cyano-6,7-dimethoxyquinoline used as a starting material was prepared as follows :-

Using an analogous procedure to that described in the portion of Example 1 that is concerned with the preparation of starting materials. 4-chloro-3-cyano-

6,7-dimethoxyquinoline (1.74 g) was reacted with 6-chloro-4-iodo-2,3-methylenedioxyaniline (2.5 g) to give 4-(6-chloro-4-iodo-2,3-methylenedioxyanilino)-3-cyano-6,7-dimethoxyquinoline as a solid (2.59 g) which gave the following characterising data; NMR Spectrum: (DMSO_d₆) 4.0 (s, 6H), 6.18 (s, 2H), 7.38 (s, 1H), 7.48 (s, 1H), 7.88 (s, 1H), 8.44 (s, 1H), 9.45 (s, 1H); Mass Spectrum: M+H⁺ 510.

The 6-chloro-4-iodo-2,3-methylenedioxyaniline used as a starting material was prepared as follows :-

Sulphuryl chloride (72.5 ml) was added dropwise during 1.7 hours to a stirred mixture of benzodioxole (100 g), aluminium trichloride (0.43 g) and diphenyl sulphide (0.55 ml). Once the reaction started with the evolution of sulphur dioxide, the reaction mixture was cooled in a water bath to a temperature of approximately 22°C. After completion of the addition, the reaction mixture was stirred at ambient temperature for 45 minutes. The reaction mixture was degassed under vacuum and filtered and the filtrate was distilled at atmospheric pressure using a Vigreux distillation column. There was thus obtained 5-chloro-1,3-benzodioxole; b.p. 185-187°C; NMR Spectrum: (CDCl₃) 6.0 (s, 2H); 6.7 (d, 1H); 6.75-6.9 (m, 2H).

A mixture of diisopropylamine (4.92 ml) and THF (100 ml) was cooled to -78°C and n-butyllithium (2.5 M in hexane, 14 ml) was added dropwise. The mixture was stirred at -78°C for 15 minutes. 5-Chloro-1,3-benzodioxole (3.73 ml) was added dropwise and the reaction mixture was stirred at -78°C for 30 minutes. Dry carbon dioxide gas was bubbled into the reaction mixture for 30 minutes. The resultant reaction mixture was allowed to warm to ambient temperature and was stirred for a further hour. Water was added and the organic solvent was evaporated. The residue was acidified to pH2 by the addition of 2N aqueous hydrochloric acid solution. The resultant solid was isolated and washed in turn with water and diethyl ether. There was thus obtained 5-chloro-1,3-benzodioxole-4-carboxylic acid (5.4 g); NMR Spectrum: (DMSO_d₆) 6.15 (s, 2H), 7.0 (m, 2H), 13.7 (br s, 1H).

A portion (1 g) of the material so obtained was dissolved in 1,4-dioxane (15 ml) and anhydrous tert-butanol (4 ml), diphenylphosphoryl azide (1.12 ml) and triethylamine (0.73 ml) were added in turn. The resultant mixture was stirred and heated to 100°C for 4 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and a 5% aqueous citric acid solution. The organic phase was washed in turn with water, a saturated aqueous sodium bicarbonate solution and a saturated brine solution, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using

a 9:1 mixture of petroleum ether (b.p. 40-60°C) and ethyl acetate as eluent. There was thus obtained tert-butyl N-(5-chloro-1,3-benzodioxol-4-yl)carbamate (1.1 g); NMR Spectrum: (DMSO_d₆) 1.45 (s, 9H), 6.1 (s, 2H), 6.85 (d, 1H), 6.95 (d, 1H), 8.75 (s, 1H).

A mixture of the material so obtained (1.1 g), trifluoroacetic acid (6 ml) and methylene chloride (20 ml) was stirred at ambient temperature for 3 hours. The solvent was evaporated and the residue was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic phase was washed with a saturated brine solution, dried over magnesium sulphate and evaporated. There was thus obtained 6-chloro-2,3-methylenedioxyaniline (0.642 g); NMR Spectrum: (DMSO_d₆) 5.15 (s, 2H), 6.0 (s, 2H), 6.25 (d, 1H), 6.75 (d, 1H).

6-Chloro-2,3-methylenedioxyaniline was reacted with benzyltrimethylammonium dichloroiodate in an analogous manner to that described in the last paragraph of the portion of Example 1 that is concerned with the preparation of starting materials. There was thus obtained 4-(6-chloro-4-iodo-2,3-methylenedioxyanilino)-3-cyano-6,7-dimethoxyquinoline which gave the following characterising data; NMR Spectrum: (DMSO_d₆) 6.04 (s, 2H), 7.0 (s, 1H).

Example 3

3-cyano-7-ethoxy-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline monohydrochloride salt

Sodium hexamethyldisilazane (1M solution in THF; 1.17 ml) was added to a stirred mixture of 4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyaniline (0.12 g), 4-chloro-3-cyano-7-ethoxy-6-methoxyquinoline (0.146 g) and DMF (8 ml) that had been cooled to 0°C and the resultant mixture was allowed to warm to ambient temperature and was stirred for 2 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with water and with a saturated brine solution, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica increasingly polar mixtures of methylene chloride and methanol as eluent. The material so obtained was dissolved in the minimum quantity of methylene chloride. The solution was diluted with diethyl ether and a solution of hydrogen chloride in diethyl ether (1M) was added. The resultant solid was isolated, washed with diethyl ether and dried. Thereby, the product was obtained the title compound (0.18 g); NMR Spectrum: (DMSO_d₆) 1.44 (t, 3H), 3.33 (s,

3H), 4.0 (s, 3H), 4.24 (q, 2H), 4.36 (s, 2H), 6.12 (s, 2H), 6.96 (d, 1H), 7.03 (d, 1H), 7.45 (s, 1H), 8.11 (s, 1H), 8.96 (s, 1H); Mass Spectrum: $M+H^+$ 432.

The 4-chloro-3-cyano-7-ethoxy-6-methoxyquinoline used as a starting material was prepared as follows :-

5 Diethyl azodicarboxylate (2.6 g) was added dropwise to a suspension of 4-chloro-3-cyano-7-hydroxy-6-methoxyquinoline (1.5 g; prepared as described in International Patent Application WO 00/68201, disclosed as compound (7) within Preparation 1 therein), ethanol (0.441 g), triphenylphosphine (2.18 g) and methylene chloride (15 ml) and the mixture was stirred at ambient temperature for 16 hours. The resultant mixture was washed with water and
10 with a saturated brine solution. The organic phase was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and ethyl acetate. There was thus obtained 4-chloro-3-cyano-7-ethoxy-6-methoxyquinoline as a solid (0.225 g); NMR Spectrum: (DMSO_d₆ at 100°C) 1.39–1.48 (m, 3H), 4.0 (s, 3H), 4.25–4.35 (m, 2H), 7.46 (s, 1H), 7.5 (s, 1H), 8.89 (s,
15 1H); Mass Spectrum: $M+H^+$ 263.

The 4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyaniline used as a starting material was prepared as follows :-

N,N-Diisopropylamine (0.231 g) was added to a stirred mixture of 4-iodo-2,3-methylenedioxyaniline (0.3 g), methyl 2-propynyl ether (0.16 g),
20 bis(triphenylphosphine)palladium(II) dichloride (0.16 g), cuprous iodide (0.065 g) and ethyl acetate (10 ml) that had been cooled to -20°C. The resultant mixture was allowed to warm to ambient temperature and was stirred for 16 hours. The reaction mixture was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic layer was washed with water and with a saturated brine solution, dried over magnesium sulphate
25 and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of isohexane and methylene chloride as eluent. There was thus obtained 4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyaniline as a gum (0.2 g); NMR Spectrum: (DMSO_d₆) 3.28 (s, 3H), 4.25 (s, 2H), 5.29 (s, 2H), 5.94 (s, 2H), 6.2 (d, 1H), 6.64 (d, 1H).

Example 4**3-cyano-6,7-dimethoxy-4-{4-[3-(1,1-dioxotetrahydro-4H-thiazin-4-yl)prop-1-ynyl]-2,3-methylenedioxyanilino}quinoline**

N,N-Diisopropylamine (0.043 g) was added to a stirred mixture of 3-cyano-4-(4-iodo-2,3-methylenedioxyanilino)-6,7-dimethoxyquinoline (0.2 g), 4-(2-propynyl)-1,1-dioxotetrahydro-4H-thiazine (0.145 g), bis(triphenylphosphine)palladium(II) dichloride (0.071 g), cuprous iodide (0.024 g) and ethyl acetate (10 ml) that had been cooled to -20°C. The resultant mixture was allowed to warm to ambient temperature and was stirred for 16 hours. The reaction mixture was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic layer was washed with water and with a saturated brine solution, dried over magnesium sulphate and evaporated. The residue was triturated under a mixture of acetonitrile and water. The resultant solid was isolated and dried. There was thus obtained the title compound as a solid (0.05 g); NMR Spectrum: (DMSO-d₆) 2.97–3.04 (m, 4H), 3.12–3.18 (m, 4H), 3.72 (s, 2H), 3.83 (s, 3H), 3.85 (s, 3H), 6.04 (s, 2H), 6.82 (d, 1H), 6.95 (d, 1H), 7.31 (s, 1H), 7.74 (s, 1H), 8.48 (s, 1H), 9.6 (s, 1H); Mass Spectrum: M+H⁺ 521.

Example 5**3-cyano-6,7-dimethoxy-4-[2,3-methylenedioxy-4-(3-morpholinoprop-1-ynyl)anilino]quinoline dihydrochloride salt**

Using an analogous procedure to that described in Example 4, 3-cyano-4-(4-iodo-2,3-methylenedioxyanilino)-6,7-dimethoxyquinoline was reacted with 4-(2-propynyl)morpholine. The reaction mixture was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic layer was washed with water and with a saturated brine solution, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. The material so obtained was dissolved in the minimum quantity of methylene chloride. The solution was diluted with diethyl ether and a solution of hydrogen chloride in diethyl ether (1M) was added. The resultant solid was isolated, washed with diethyl ether and dried. There was thus obtained the title compound as a solid (0.065 g); NMR Spectrum: (DMSO-d₆ and CD₃CO₂D) 3.24–3.29 (m, 4H), 3.9–3.95 (m,

4H), 4.0 (s, 3H), 4.01 (s, 3H), 4.28 (s, 2H), 6.1 (s, 2H), 6.95 (d, 1H), 7.05 (d, 1H), 7.49 (s, 1H), 7.5–7.65 (m, 1H), 8.06 (s, 1H), 8.67 (s, 1H); Mass Spectrum: M-H⁺ 471.

Example 6

5 3-cyano-6,7-dimethoxy-4-[2,3-methylenedioxy-4-(3-piperazin-1-ylprop-1-ynyl)anilino]quinoline dihydrochloride salt

Using an analogous procedure to that described in Example 1, 3-cyano-4-(4-iodo-2,3-methylenedioxyanilino)-6,7-dimethoxyquinoline was reacted with 1-(2-propynyl)piperazine (J. Med. Chem., 1993, 36, 610-616). The reaction mixture was
10 partitioned between methylene chloride and a 2N aqueous hydrochloric acid solution. The organic layer was dried over magnesium sulphate and evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a saturated methanolic ammonia solution as eluent. The material so obtained was dissolved in the minimum quantity of methylene chloride. The solution was diluted with
15 diethyl ether and a solution of hydrogen chloride in diethyl ether (1M) was added. The resultant solid was isolated, washed with diethyl ether and dried. There was thus obtained the title compound; NMR Spectrum: (DMSO-d₆ and CD₃CO₂D) 3.28–3.44 (m, 8H), 3.99 (s, 3H), 4.0 (s, 3H), 4.27 (br s, 2H), 6.15 (s, 2H), 7.04 (d, 1H), 7.14 (d, 1H), 7.5 (s, 1H), 8.24 (s, 1H), 9.05 (s, 1H); Mass Spectrum: M-H⁺ 470.

20

Example 7

4-[4-(5-chloropent-1-ynyl)-2,3-methylenedioxyanilino]-3-cyano-6,7-dimethoxyquinoline


Using an analogous procedure to that described in Example 4, 3-cyano-4-(4-iodo-2,3-methylenedioxyanilino)-6,7-dimethoxyquinoline was reacted with
25 5-chloropent-1-yne. The reaction mixture was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic layer was washed with water and with a saturated brine solution, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent. There was thus obtained the title compound as
30 a gum in 69% yield; Mass Spectrum: M+H⁺ 450.

Example 8**3-cyano-6,7-dimethoxy-4-[2,3-methylenedioxy-4-(5-morpholinopent-1-ynyl)anilino]quinoline dihydrochloride salt**

Morpholine (5 ml) was added to a mixture of 4-[4-(5-chloropent-1-ynyl)-2,3-methylenedioxyanilino]-3-cyano-6,7-dimethoxyquinoline (0.11 g) and sodium iodide (0.073 g) and the reaction mixture was stirred at ambient temperature for 16 hours. The resultant mixture was evaporated and the residue partitioned between methylene chloride and water. The organic phase was washed with water and with a saturated brine solution, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a saturated methanolic ammonia solution as eluent. The material so obtained was dissolved in the minimum quantity of methylene chloride. The solution was diluted with diethyl ether and a solution of hydrogen chloride in diethyl ether (1M) was added. The resultant solid was isolated, washed with diethyl ether and dried. There was thus obtained the title compound as a solid (0.105 g); NMR Spectrum: (DMSO_d₆ and CD₃CO₂D) 1.98–2.04 (m, 2H), 2.56–2.65 (m, 2H), 3.04–3.16 (m, 2H), 3.17–3.26 (m, 2H), 3.39–3.51 (m, 2H), 3.69–4.02 (m, 10H), 6.06 (s, 2H), 6.9 (d, 1H), 6.98 (d, 1H), 7.37 (s, 1H), 7.95 (s, 1H), 8.75 (s, 1H); Mass Spectrum: M+H⁺ 501.

Example 9

Using an analogous procedure to that described in Example 3, the appropriate 4-chloro-3-cyanoquinoline was reacted with the appropriate 2,3-methylenedioxyaniline to give the compounds described in Table I. Unless otherwise stated, each compound described in Table I was obtained as a dihydrochloride salt.

Table I

| Compound No. & Note | R ¹ | (R ³) _n |
|------------------------|--|-----------------------------------|
| [1] | 3-(4-methylpiperazin-1-yl)propoxy | 4-(3-methoxyprop-1-ynyl) |
| [2] | 3-morpholinopropoxy | 4-(3-methoxyprop-1-ynyl) |
| [3] | 3-morpholinopropoxy | 6-chloro-4-(3-methoxyprop-1-ynyl) |
| [4] | 3-(1,1-dioxotetrahydro-4H-thiazin-4-yl)propoxy | 4-(3-methoxyprop-1-ynyl) |
| [5] | 2-fluoroethoxy | 4-(3-methoxyprop-1-ynyl) |
| [6] | 3-(3-oxopiperazin-1-yl)propoxy | 4-(3-methoxyprop-1-ynyl) |
| [7] | 3-(3-oxopiperazin-1-yl)propoxy | 6-chloro-4-(3-methoxyprop-1-ynyl) |
| [8] | 2-(2-methoxyethoxy)ethoxy | 4-(3-methoxyprop-1-ynyl) |
| [9] | 3-chloropropoxy | 4-(3-methoxyprop-1-ynyl) |
| [10] | 2-(2-chloroethoxy)ethoxy | 4-(3-methoxyprop-1-ynyl) |

Notes

[1] The product was obtained as a trihydrochloride salt and gave the following characterising data; NMR Spectrum: (DMSO-d₆) 2.27–2.38 (m, 2H), 2.83 (s, 3H), 3.23–3.85 (m, 10H), 3.34 (s, 3H), 4.01 (s, 3H), 4.3 (t, 2H), 4.35 (s, 2H), 6.11 (s, 2H), 6.97 (d, 1H), 7.01 (d, 1H), 7.53 (s, 1H), 8.21 (s, 1H), 8.94 (s, 1H); Mass Spectrum: M-H⁺ 542.

The 4-chloro-3-cyano-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline used as a starting material was prepared as follows :-

A mixture of 3-bromopropanol (20 ml), N-methylpiperazine (29 ml), potassium carbonate (83 g) and ethanol (200 ml) was stirred and heated to reflux for 20 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the residue was triturated under diethyl ether. The resultant mixture was filtered and the filtrate was evaporated. The residue was purified by distillation at about 60-70°C under about 0.2 mm Hg to give 1-(3-hydroxypropyl)-4-methylpiperazine (17 g); NMR Spectrum: (CDCl₃) 1.72 (m, 2H), 2.3 (s, 3H), 2.2-2.8 (m, 8H), 2.6 (t, 2H), 3.8 (t, 2H), 5.3 (br s, 1H).

A solution of diisopropyl azodicarboxylate (12.1 ml) in methylene chloride (50 ml) was added dropwise during 30 minutes to a stirred mixture of 4-chloro-3-cyano-7-hydroxy-6-methoxyquinoline (12 g), 1-(3-hydroxypropyl)-4-methylpiperazine (9.7 g), triphenylphosphine (16.1 g) and methylene chloride (200 ml) that had been cooled to 5°C.

The resultant mixture was allowed to warm to ambient temperature and was then stirred for 1 hour. Further portions of diisopropyl azodicarboxylate (1.2 ml) and triphenylphosphine (1.6 g) were added and the mixture was stirred at ambient temperature for a further 1 hour. The mixture was poured into water and the organic layer was separated, washed with a saturated brine solution, dried over magnesium sulphate and evaporated. The material so obtained was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained the required starting material as a solid (14.5 g); NMR Spectrum: (DMSO_d₆) 1.95 (m, 2H), 2.13 (s, 3H), 2.24-2.5 (m, 10H), 4.0 (s, 3H), 4.25 (t, 2H), 7.43 (s, 1H), 7.51 (s, 1H), 8.95 (s, 1H); Mass Spectrum: M+H⁺ 375 and 377.

[2] 4-Chloro-3-cyano-6-methoxy-7-(3-morpholinopropoxy)quinoline (International Patent Application WO 00/68201, page 52) was used as a starting material. The product gave the following characterising data; NMR Spectrum: (DMSO_d₆) 2.3-2.38 (m, 2H), 3.04-3.14 (m, 2H), 3.25-3.31 (m, 2H), 3.35 (s, 3H), 3.44-3.52 (m, 2H), 3.78-3.86 (m, 2H), 3.98 (d, 2H), 4.01, (s, 3H), 4.3 (t, 2H), 4.36 (s, 2H), 6.14 (s, 2H), 7.0 (d, 1H), 7.03 (d, 1H), 7.55 (s, 1H), 8.21 (s, 1H), 8.94 (s, 1H); Mass Spectrum: M+H⁺ 531.

[3] The product gave the following characterising data; NMR Spectrum: (DMSO_d₆) 2.26-2.35 (m, 2H), 3.03-3.14 (m, 2H), 3.22-3.31 (m, 2H), 3.33 (s, 3H), 3.44-3.51 (m, 2H), 3.81 (t, 2H), 3.91-4.0 (m, 5H), 4.3 (t, 2H), 4.36 (s, 2H), 6.2 (d, 2H), 7.22 (s, 1H), 7.51 (s, 1H), 8.15 (s, 1H), 8.86 (s, 1H); Mass Spectrum: M-H⁻ 563 and 565.

The 6-chloro-4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyaniline used as a starting material was prepared as follows :-

N,N-Diisopropylamine (0.68 g) was added to a stirred mixture of 6-chloro-4-iodo-2,3-methylenedioxyaniline (1 g), methyl 2-propynyl ether (0.471 g), bis(triphenylphosphine)palladium(II) dichloride (0.472 g), cuprous iodide (0.192 g) and ethyl acetate (20 ml) that had been cooled to -20°C. The resultant mixture was allowed to warm to ambient temperature and was stirred for 16 hours. The reaction mixture was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic layer was washed with water and with a saturated brine solution, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of isohexane and methylene chloride as eluent. There was thus obtained 6-chloro-4-(3-methoxyprop 1-ynyl) 2,3-methylenedioxyaniline as a solid

(0.2 g); NMR Spectrum: (DMSO_d₆) 3.28 (s, 3H), 4.26 (s, 2H), 5.52 (s, 2H), 6.05 (s, 2H), 6.93 (s, 1H).

[4] The product gave the following characterising data; NMR Spectrum: (DMSO_d₆) 2.2–2.27 (m, 2H), 3.16–3.2 (m, 2H), 3.36 (s, 3H), 3.37–3.54 (m, 8H), 4.0 (s, 3H), 4.3–4.37 (m, 4H), 6.19 (s, 2H), 6.8 (d, 1H), 7.0 (d, 1H), 7.46 (s, 1H), 8.0 (s, 1H), 8.74 (s, 1H); Mass Spectrum: M-H⁺ 577.

The 4-chloro-3-cyano-7-[3-(1,1-dioxotetrahydro-4H-thiazin-4-yl)propoxy]-6-methoxyquinoline used as a starting material was prepared as follows :-

A mixture of 3-aminopropan-1-ol (0.65 ml) and divinyl sulphone (1 g) was heated to 110°C for 45 minutes. The mixture was allowed to cool to ambient temperature and was purified by column chromatography on silica using a 19:1 mixture of methylene chloride and methanol as eluent. There was thus obtained 4-(3-hydroxypropyl)-1,1-dioxotetrahydro-4H-thiazine (0.8 g); NMR Spectrum: (CDCl₃) 1.7–1.8 (m, 2H), 2.73 (t, 2H), 3.06 (br s, 8H), 3.25 (s, 1H), 3.78 (t, 2H); Mass Spectrum: M+H⁺ 194.

Diethyl azodicarboxylate (1.72 g) was added dropwise to a suspension of 4-chloro-3-cyano-7-hydroxy-6-methoxyquinoline (1 g), 4-(3-hydroxypropyl)-1,1-dioxotetrahydro-4H-thiazine (1.23 g), triphenylphosphine (1.45 g) and methylene chloride (10 ml) and the mixture was stirred at ambient temperature for 16 hours. The resultant mixture was washed with water and with a saturated brine solution. The organic phase was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride, ethyl acetate and a saturated methanolic ammonia solution as eluent. The material so obtained was triturated under diethyl ether. There was thus obtained 4-chloro-3-cyano-7-[3-(1,1-dioxotetrahydro-4H-thiazin-4-yl)propoxy]-6-methoxyquinoline (0.15 g); NMR Spectrum: (DMSO_d₆) 1.96 (m, 2H), 2.64 (t, 2H), 2.88–2.93 (m, 4H), 3.07–3.12 (m, 4H), 4.0 (s, 3H), 4.29 (t, 2H), 7.44 (s, 1H), 7.55 (s, 1H), 8.96 (s, 1H); Mass Spectrum: M+H⁺ 410.

[5] The product was obtained as a monohydrochloride salt and gave the following characterising data; NMR Spectrum: (DMSO_d₆) 3.33 (s, 3H), 4.0 (s, 3H), 4.35 (s, 2H), 4.39–4.43 (m, 1H), 4.49–4.53 (m, 1H), 4.75–4.8 (m, 1H), 4.91–4.96 (m, 1H), 6.12 (s, 2H), 6.96 (d, 1H), 7.01 (d, 1H), 7.48 (s, 1H), 8.13 (s, 1H), 8.94 (s, 1H); Mass Spectrum: M+H⁺ 450.

The 4-chloro-3-cyano-7-(2-fluoroethoxy)-6-methoxyquinoline used as a starting material was prepared by the reaction of 4-chloro-3-cyano-7-hydroxy-6-methoxyquinoline and 2-fluoroethanol using an analogous procedure to that described in Note [4] immediately above

except that the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent. The material so obtained gave the following characterising data; NMR Spectrum: (DMSO-d₆) 4.01 (s, 3H), 4.43–4.48 (m, 1H), 4.53–4.58 (m, 1H), 4.74–4.78 (m, 1H), 4.9–4.94 (m, 1H), 7.42 (s, 1H), 7.56 (s, 1H),
5 8.96 (s, 1H); Mass Spectrum: M+H⁺ 281.

[6] The product was obtained as a free base after chromatographic purification and was not converted into a hydrochloride salt. The product gave the following characterising data; NMR Spectrum: (DMSO-d₆ and CD₃CO₂D) 1.96–2.02 (m, 2H), 2.6–2.68 (m, 4H), 3.03 (s, 2H), 3.21 (m, 2H), 3.34 (s, 3H), 3.94 (s, 3H), 4.21 (t, 2H), 4.3 (s, 2H), 6.01 (s, 2H), 6.76 (d,
10 1H), 6.91 (d, 1H), 7.34 (s, 1H), 7.71 (s, 1H), 8.41 (s, 1H); Mass Spectrum: M-H⁺ 542.

The 4-chloro-3-cyano-6-methoxy-7-[3-(3-oxopiperazin-1-yl)propoxy]quinoline used as a starting material was prepared by the reaction of 4-chloro-3-cyano-7-hydroxy-6-methoxyquinoline and 4-(3-hydroxypropyl)piperazin-2-one (Tet. Letters, 1994, 35, 9545) using an analogous procedure to that described in Note [4] immediately above. The material
15 so obtained gave the following characterising data; NMR Spectrum: (DMSO-d₆) 1.92–2.03 (m, 2H), 2.49–2.59 (m, 4H), 2.94 (s, 2H), 3.1–3.17 (m, 2H), 4.0 (s, 3H), 4.27 (t, 2H), 7.42 (s, 1H), 7.51 (s, 1H), 7.69 (s, 1H), 8.95 (s, 1H); Mass Spectrum: M+H⁺ 375.

[7] The product gave the following characterising data; NMR Spectrum: (DMSO-d₆) 2.29–2.36 (m, 2H), 3.21–3.41 (m, 5H), 3.55–3.9 (m, 4H), 3.99 (s, 3H), 4.28–4.32 (m, 2H),
20 4.35 (s, 2H), 5.99 (s, 1H), 6.01 (s, 1H), 6.01 (s, 2H), 7.21 (s, 1H), 7.48 (s, 1H), 8.11 (s, 1H), 8.81 (s, 1H); Mass Spectrum: M+H⁺ 578 and 580.

[8] The product was obtained as a monohydrochloride salt and gave the following characterising data; NMR Spectrum: (DMSO-d₆ and CD₃CO₂D) 3.26 (s, 3H), 3.36 (s, 3H), 3.49 (t, 2H), 3.54 (t, 2H), 3.86 (t, 2H), 4.0 (s, 3H), 4.32–4.36 (m, 4H), 6.09 (s, 2H), 6.91 (d,
25 1H), 7.0 (d, 1H), 7.48 (s, 1H), 8.01 (s, 1H), 8.75 (s, 1H); Mass Spectrum: M+H⁺ 506.

The 4-chloro-3-cyano-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinoline used as a starting material was prepared by the reaction of 4-chloro-3-cyano-7-hydroxy-6-methoxyquinoline and 2-(2-methoxyethoxy)ethanol using an analogous procedure to that described in Note [4] immediately above except that the residue was purified by column
30 chromatography on silica using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent. The material so obtained gave the following characterising data; NMR Spectrum: (DMSO-d₆) 3.23 (s, 3H), 3.46 (m, 2H), 3.61 (m, 2H), 3.82 (m, 2H), 4.0 (s, 3H), 4.34 (t, 2H), 7.42 (s, 1H), 7.55 (s, 1H), 8.95 (s, 1H).

[9] The product was obtained as a free base after chromatographic purification and was not converted into a hydrochloride salt. The product gave the following characterising data;

NMR Spectrum: (DMSO_d₆) 2.25 (m, 2H), 3.32 (s, 3H), 3.8 (t, 2H), 3.92 (s, 3H), 4.27 (t, 2H), 4.34 (s, 2H), 6.05 (s, 2H), 6.82 (d, 1H), 6.96 (d, 1H), 7.35 (s, 1H), 7.74 (s, 1H), 8.47 (s, 1H), 9.60 (s, 1H); Mass Spectrum: M+H⁺ 480.

The 4-chloro-7-(3-chloropropoxy)-3-cyano-6-methoxyquinoline used as a starting material was prepared as follows :-

A mixture of 4-chloro-3-cyano-7-hydroxy-6-methoxyquinoline (0.2 g), potassium tert-butoxide (0.1 g) and DMF (8 ml) was stirred at ambient temperature for 15 minutes.

10 1-Bromo-3-chloropropane (0.134 g) was added and the reaction mixture was stirred at ambient temperature for 16 hours. The resultant mixture was evaporated and the residue was partitioned between methylene chloride and an aqueous sodium bicarbonate solution. The organic layer was dried using magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of ethyl acetate and
15 hexane. There was thus obtained the required starting material (0.131 g); NMR Spectrum: (DMSO_d₆) 2.3 (m, 2H), 3.8 (m, 2H), 4.0 (s, 3H), 4.35 (m, 2H), 7.42 (s, 1H), 7.68 (s, 1H), 8.95 (s, 1H); Mass Spectrum: M+H⁺ 311.

[10] The product was obtained as a free base after chromatographic purification and was not converted into a hydrochloride salt. The product gave the following characterising data;

20 NMR Spectrum: (DMSO_d₆) 3.32 (s, 3H), 3.72–3.78 (m, 4H), 3.85–3.89 (m, 2H), 3.91 (s, 3H), 4.28 (t, 2H), 4.34 (s, 2H), 6.05 (s, 2H), 6.82 (d, 1H), 6.95 (d, 1H), 7.35 (s, 1H), 7.74 (s, 1H), 8.47 (s, 1H), 9.60 (s, 1H); Mass Spectrum: M+H⁺ 510.

The 4-chloro-7-[2-(2-chloroethoxy)ethoxy]-3-cyano-6-methoxyquinoline used as a starting material was prepared by the reaction of 4-chloro-3-cyano-7-hydroxy-

25 6-methoxyquinoline and 2-(2-chloroethoxy)ethanol using an analogous procedure to that described in Note [4] immediately above except that the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent. The material so obtained gave the following characterising data; NMR Spectrum: (DMSO_d₆) 3.72–3.8 (m, 4H), 3.88–3.93 (m, 2H), 4.0 (s, 3H), 4.33–4.39 (m, 2H),
30 7.4 (s, 1H), 7.55 (s, 1H), 8.94 (s, 1H); Mass Spectrum: M+H⁺ 341.

Example 10

3-cyano-7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline dihydrochloride salt

A mixture of 7-(3-chloropropoxy)-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline (0.14 g), 1-(2-fluoroethyl)piperazine trifluoroacetic acid salt (0.158 g), diisopropylethylamine (0.189 g), sodium iodide (0.02 g) and 2-methoxyethanol (20 ml) was stirred and heated to 100°C for 30 hours. The cooled mixture was evaporated and the resultant residue was partitioned between ethyl acetate and water. The organic layer was dried over magnesium sulphate and evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. The material so obtained was dissolved in the minimum quantity of methylene chloride. The solution was diluted with diethyl ether and a solution of hydrogen chloride in diethyl ether (1M) was added. The resultant solid was isolated, washed with diethyl ether and dried. There was thus obtained the title compound (0.045 g); NMR Spectrum: (DMSO_d₆ and CF₃CO₂D at 100°C) 2.22–2.31 (m, 2H), 2.98–3.1 (m, 6H), 3.16–3.21 (m, 2H), 3.25–3.31 (m, 4H), 3.36 (s, 3H), 3.99 (s, 3H), 4.3–4.34 (m, 4H), 4.6 (t, 1H), 4.72 (t, 1H), 6.08 (s, 2H), 6.9 (d, 1H), 6.98 (d, 1H), 7.49 (s, 1H), 7.96 (s, 1H), 8.69 (s, 1H); Mass Spectrum: M+H⁺ 576.

The 1-(2-fluoroethyl)piperazine trifluoroacetic acid used as a starting material was prepared as follows :-

A mixture of 1-(tert-butoxycarbonyl)piperazine (5 g), 1-bromo-2-fluoroethane (5.11 g), potassium carbonate (9.26 g) and acetonitrile (60 ml) was stirred and heated to 60°C for 4 hours. The reaction mixture was cooled to ambient temperature and filtered and the filtrate was evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of isohexane and ethyl acetate as eluent. There was thus obtained 4-(tert-butoxycarbonyl)-1-(2-fluoroethyl)piperazine as a solid (3.7 g); NMR Spectrum: (DMSO_d₆ and CD₃CO₂D) 1.37 (s, 9H), 2.34–2.4 (m, 4H), 2.56 (t, 1H), 2.67 (t, 1H), 3.25–3.34 (m, 4H), 4.42 (t, 1H), 4.58 (t, 1H).

Trifluoroacetic acid (20 ml) was added to a mixture of 4-(tert-butoxycarbonyl)-1-(2-fluoroethyl)piperazine (3.7 g), triethylsilane (8 ml) and methylene chloride (100 ml) and the resultant mixture was stirred at ambient temperature for 1.5 hours. The mixture was evaporated and the residue was triturated under diethyl ether. The solid so obtained was

isolated, washed with diethyl ether and dried. There was thus obtained

1-(2-fluoroethyl)piperazine trifluoroacetic acid salt as a solid (6.0 g); NMR Spectrum: (DMSO_d₆ and CD₃CO₂D) 3.0–3.31 (m, 10H), 4.59 (m, 1H), 4.75 (m, 1H).

5 Example 11

7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline dihydrochloride salt

Using an analogous procedure to that described in Example 10, 7-(3-chloropropoxy)-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline was
10 reacted with 1-acetylpiperazine to give the title compound in 58% yield; NMR Spectrum: (DMSO_d₆ and CF₃CO₂D at 100°C) 2.04 (s, 3H), 2.3–2.37 (m, 2H), 3.27–3.37 (m, 9H), 3.74–3.84 (m, 4H), 3.96 (s, 3H), 4.3–4.36 (m, 4H), 6.04 (s, 2H), 6.89 (d, 1H), 6.96 (d, 1H), 7.51 (s, 1H), 7.96 (s, 1H), 8.66 (s, 1H); Mass Spectrum: M+H⁺ 572.

15 Example 12

3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]-
7-[2-(2-pyrrolidin-1-ylethoxy)ethoxy]quinoline dihydrochloride salt

Pyrrolidine (10 ml) was added to a mixture of 7-[2-(2-chloroethoxy)ethoxy]-
3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline
20 (0.225 g) and sodium iodide (0.133 g) and the reaction mixture was stirred at ambient
temperature for 24 hours. The reaction mixture was evaporated and the residue was triturated
under methylene chloride. The resultant solid was washed with water and dried. The material
so obtained was dissolved in the minimum quantity of ethyl acetate and a solution of hydrogen
chloride in diethyl ether (1M) was added. The resultant solid was isolated, washed with
25 diethyl ether and dried. There was thus obtained the title compound as a solid (0.145 g);
NMR Spectrum: (DMSO_d₆ and CD₃CO₂D at 100°C) 1.84–1.89 (m, 4H), 3.29–3.39 (m, 9H),
3.88 (m, 2H), 3.94 (m, 2H), 3.96 (s, 3H), 4.3 (s, 2H), 4.36 (m, 2H), 6.04 (s, 2H), 6.84 (d, 1H),
6.94 (d, 1H), 7.46 (s, 1H), 7.87 (s, 1H), 8.56 (s, 1H); Mass Spectrum: M+H⁺ 545.


Example 13

3-[4-(3-cyano-6,7-dimethoxyquinolin-4-ylamino)-2,3-methylenedioxyphenyl]acrylonitrile

A mixture of 3-cyano-4-(4-iodo-2,3-methylenedioxyanilino)-6,7-dimethoxyquinoline (0.2 g), acrylonitrile (0.2 ml), triethylamine (0.2 ml), palladium(II) acetate (0.01 g) and DMF (2 ml) was stirred and heated to 115°C for 3 hours. The reaction mixture was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of hexane and ethyl acetate as eluent. The material so obtained was triturated under diethyl ether. There was thus obtained the title compound, in the form of a 4:1 mixture of trans and cis isomers and as a yellow solid (0.095 g); NMR Spectrum: (DMSO-d₆, data relating to the major trans isomer) 3.91 (s, 3H), 3.93 (s, 3H), 6.12 (s, 2H), 6.26 (d, 1H), 6.88 (d, 1H), 7.14 (d, 1H), 7.35 (s, 1H), 7.56 (d, 1H), 7.7 (s, 1H), 8.51 (s, 1H), 9.7 (s, 1H); Mass Spectrum: M+H⁺ 401.

Example 14

Using an analogous procedure to that described in Example 13, the appropriate 4-(4-iodo-2,3-methylenedioxyanilino)-3-cyano-6,7-dimethoxyquinoline was reacted with the appropriate olefin to give the compounds described in Table II.

Table II

| Compound No. & Note | R ¹ | (R ³) _n |
|---------------------|----------------|------------------------------------|
| [1] | methoxy | 6-chloro-4-(2-cyanovinyl) |
| [2] | methoxy | 4-(2-methoxycarbonylviny) |
| [3] | methoxy | 6-chloro-4-(2-methoxycarbonylviny) |
| [4] | methoxy | 4-(2-propionylviny) |

- [1] The required olefin was acrylonitrile. The product was obtained as the trans isomer and gave the following characterising data; NMR Spectrum: (DMSO_d₆) 3.94 (s, 3H), 3.98 (s, 3H), 6.17 (s, 2H), 6.32 (d, 1H), 7.33 (s, 1H), 7.36 (s, 1H), 7.49 (d, 1H), 7.84 (s, 1H), 8.39 (s, 1H), 9.6 (br s, 1H); Mass Spectrum: M+H⁺ 435 and 437.
- 5 [2] The required olefin was methyl acrylate. The product was obtained as the trans isomer and gave the following characterising data; NMR Spectrum: (DMSO_d₆) 3.72 (s, 3H), 3.91 (s, 3H), 3.93 (s, 3H), 6.12 (s, 2H), 6.29 (d, 1H), 6.88 (d, 1H), 7.22 (d, 1H), 7.35 (s, 1H), 7.59 (d, 1H), 7.74 (s, 1H), 8.51 (s, 1H), 9.68 (s, 1H); Mass Spectrum: M+H⁺ 434.
- [3] The required olefin was methyl acrylate. The reaction solvent was a 6:1 mixture of
10 acetonitrile and DMF and the reaction mixture was heated to 80°C for 5 hours. The product was obtained as the trans isomer and gave the following characterising data; NMR Spectrum: (DMSO_d₆) 3.74 (s, 3H), 3.95 (s, 6H), 6.22 (d, 2H), 6.7 (d, 1H), 7.33 (s, 1H), 7.53 (s, 1H), 7.59 (d, 1H), 7.86 (s, 1H), 8.44 (s, 1H), 9.45 (s, 1H); Mass Spectrum: M+H⁺ 468 and 470.
- [4] The required olefin was ethyl vinyl ketone. The product was obtained as the trans
15 isomer and gave the following characterising data; NMR Spectrum: (DMSO_d₆) 1.03 (t, 3H), 2.70 (q, 2H), 3.91 (s, 3H), 3.93 (s, 3H), 6.12 (s, 2H), 6.83-6.93 (m, 2H), 7.22 (d, 1H), 7.35 (s, 1H), 7.52 (d, 1H), 7.74 (s, 1H), 8.51 (s, 1H), 9.65 (s, 1H); Mass Spectrum: M+H⁺ 432.

Example 15

- 20 (2E)-3-[4-(3-cyano-6,7-dimethoxyquinolin-4-ylamino)-2,3-methylenedioxyphenyl]acrylic acid
- A mixture of methyl (2E)-3-[4-(3-cyano-6,7-dimethoxyquinolin-4-ylamino)-2,3-methylenedioxyphenyl]acrylate (0.75 g), a 1N aqueous sodium hydroxide solution (12 ml) and methanol (45 ml) was stirred and warmed to 40°C for 12 hours. The reaction mixture was evaporated. Water was added and the mixture was acidified by the addition of 2N aqueous
25 hydrochloric acid solution. The resultant precipitate was isolated and dried. There was thus obtained the title compound as a solid (0.703 g); NMR Spectrum: (DMSO_d₆) 3.98 (s, 6H), 6.19 (s, 2H), 6.59 (d, 1H), 7.02 (d, 1H), 7.28 (d, 1H), 7.48 (s, 1H), 7.55 (d, 1H), 8.09 (s, 1H), 8.95 (s, 1H); Mass Spectrum: M+H⁺ 420.

Example 16

N-[(2E)-3-[4-(3-cyano-6,7-dimethoxyquinolin-4-ylamino)-
2,3-methylenedioxyphenyl]acryloyl]morpholine

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.196 g) was added
5 to a mixture of (2E)-3-[4-(3-cyano-6,7-dimethoxyquinolin-4-ylamino)-
2,3-methylenedioxyphenyl]acrylic acid (0.35 g), morpholine (0.36 ml), N-methylmorpholine
(0.112 ml), 1-hydroxybenzotriazole (0.112 ml), DMF (2 ml) and methylene chloride (10 ml)
and the reaction mixture was stirred at ambient temperature for 12 hours. The resultant
mixture was partitioned between methylene chloride and water. The organic layer was dried
10 over magnesium sulphate and evaporated and the residue was purified by column
chromatography on silica using increasingly polar mixtures of methylene chloride and
methanol as eluent. The material so obtained was triturated under diethyl ether. There was
thus obtained the title compound as a solid (0.031 g); NMR Spectrum: (DMSO_d₆) 3.66 (s,
8H), 3.96 (s, 6H), 6.09 (s, 2H), 6.87 (d, 1H), 7.19 (d, 1H), 7.28 (d, 1H), 7.34 (s, 1H), 7.49 (d,
15 1H), 7.77 (s, 1H), 8.48 (s, 1H), 9.63 (s, 1H); Mass Spectrum: M+H⁺ 489.

Example 17

(2E)-3-[4-(3-cyano-6,7-dimethoxyquinolin-4-ylamino)-2,3-methylenedioxyphenyl]-
N-(2-methoxyethyl)acrylamide

20 Using an analogous procedure to that described in Example 16, (2E)-3-[4-(3-cyano-
6,7-dimethoxyquinolin-4-ylamino)-2,3-methylenedioxyphenyl]acrylic acid was reacted with
2-methoxyethylamine to give the title compound in 64% yield; NMR Spectrum: (DMSO_d₆)
3.22-3.43 (m, 7H), 3.95 (s, 3H), 3.96 (s, 3H), 6.1 (s, 2H), 6.74 (d, 1H), 6.87 (d, 1H), 7.07 (d,
1H), 7.32 (s, 2H), 7.73 (s, 1H), 8.22 (t, 1H), 8.48 (s, 1H), 9.62 (s, 1H); Mass Spectrum:
25 M+H⁺ 477.

Example 18

(2E)-3-[4-(3-cyano-6,7-dimethoxyquinolin-4-ylamino)-2,3-methylenedioxyphenyl]-
N-(2-methoxyethyl)-N-methylacrylamide

30 Using an analogous procedure to that described in Example 16, (2E)-3-[4-(3-cyano-
6,7-dimethoxyquinolin-4-ylamino)-2,3-methylenedioxyphenyl]acrylic acid was reacted with
N-(2-methoxyethyl)-N-methylamine to give the title compound in 47% yield; NMR Spectrum:
(DMSO_d₆) 1.94 (s, 3H), 3.08 (s, 3H), 3.17 (s, 3H), 3.43-3.65 (m, 7H), 3.95 (s, 3H), 3.96 (s, 3H), 6.1 (s, 2H), 6.74 (d, 1H), 6.87 (d, 1H), 7.07 (d, 1H), 7.32 (s, 2H), 7.73 (s, 1H), 8.22 (t, 1H), 8.48 (s, 1H), 9.62 (s, 1H).

(s, 3H), 6.1 (s, 2H), 6.84 (d, 1H), 7.16 (d, 1H), 7.25 (d, 1H), 7.33 (s, 1H), 7.43 (d, 1H), 7.76 (s, 1H), 8.48 (s, 1H), 9.62 (s, 1H); Mass Spectrum: $M+H^+$ 491.

Example 19

5 3-cyano-6,7-dimethoxy-4-[5-(3-methoxyprop-1-ynyl)-
2,3-methylenedioxyanilino]quinoline

A mixture of 4-(5-bromo-2,3-methylenedioxyanilino)-3-cyano-
6,7-dimethoxyquinoline (0.15 g), methyl 2-propynyl ether (0.049 g),
tetrakis(triphenylphosphine)palladium(0) (0.02 g) and pyrrolidine (2 ml) was stirred and
10 heated to 80°C for 8 hours. The resultant mixture was cooled to ambient temperature, poured
into a dilute aqueous ammonium chloride solution and extracted with ethyl acetate. The
organic phase was washed with water and with a saturated brine solution, dried over
magnesium sulphate and evaporated. The residue was purified by column chromatography on
silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There
15 was thus obtained the title compound as a solid (0.032 g); NMR Spectrum: ($CDCl_3$) 3.4 (s,
3H), 3.77 (s, 3H), 4.04 (s, 3H), 4.24 (s, 2H), 5.97 (s, 2H), 6.65 (br s, 1H), 6.73 (d, 1H), 6.78
(d, 1H), 6.99 (s, 1H), 7.38 (s, 1H), 8.63 (s, 1H); Mass Spectrum: $M+H^+$ 418.

The 4-(5-bromo-2,3-methylenedioxyanilino)-3-cyano-6,7-dimethoxyquinoline used as
a starting material was prepared as follows :-

20 A mixture of 6-bromo-1,3-benzodioxole-4-carboxylic acid [Khim. Geterotsikl. Soedin
1979, 9, 1183-8 (Chemical Abstracts 92, 94280); 0.92 g], diphenylphosphoryl azide (1.08 g),
tert-butanol (3 ml), triethylamine (0.34 g) and toluene (15 ml) were stirred and heated at
100°C for 4 hours. The resultant mixture was evaporated and the residue was partitioned
between methyl tert-butyl ether and a 5% aqueous citric acid solution. The organic phase was
25 washed with water and a saturated aqueous sodium bicarbonate solution, dried over
magnesium sulphate and evaporated. The residual oil was purified by column
chromatography on silica using a 5:1 mixture of isohexane and ethyl acetate as eluent. There
was thus obtained tert-butyl N-(6-bromo-1,3-benzodioxol-4-yl)carbamate (0.6 g); NMR
Spectrum: ($CDCl_3$) 1.52 (s, 9H), 5.95 (s, 2H), 6.39 (br s, 1H), 6.7 (d, 1H), 7.73 (br s, 1H).


30 A mixture of the material so obtained, trifluoroacetic acid (3 ml) and methylene
chloride (8 ml) was stirred at ambient temperature for 1 hour. The solvent was evaporated
and the residue was partitioned between methyl tert-butyl ether and a saturated aqueous
sodium bicarbonate solution. The organic phase was washed with a saturated brine solution,

dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 4:1 mixture of isohexane and ethyl acetate as eluent. There was thus obtained 5-bromo-2,3-methylenedioxyaniline (0.318 g) as a colourless solid; NMR Spectrum: (CDCl₃) 3.6 (br s, 2H), 5.92 (s, 2H), 6.27 (m, 2H).

- 5 Using an analogous procedure to that described in Example 3, 4-chloro-3-cyano-6,7-dimethoxyquinoline (0.65 g) was reacted with 5-bromo-2,3-methylenedioxyaniline (0.587 g). The free base obtained after chromatographic purification was not converted into the dihydrochloride salt. There was thus obtained 4-(5-bromo-2,3-methylenedioxyanilino)-3-cyano-6,7-dimethoxyquinoline as a solid (1.16 g);
- 10 NMR Spectrum: (CDCl₃) 3.83 (s, 3H), 4.05 (s, 3H), 5.98 (s, 2H), 6.76 (d, 1H), 6.84 (d, 1H), 6.9 (br s, 1H), 7.06 (s, 1H), 7.39 (s, 1H), 8.64 (s, 1H); Mass Spectrum: M+H⁺ 428 and 430.

CLAIMS

1. A quinoline derivative of the Formula I



- 5 wherein each of Z^1 , m , R^1 , n , R^3 , Z^2 and R^{14} have any of the meanings defined hereinbefore in the description.

2. A process for the preparation of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, according to claim 1 which comprises any one of the
10 process variants (a) to (h) defined hereinbefore in the description.

3. A pharmaceutical composition which comprises a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, according to claim 1 in association with a pharmaceutically-acceptable diluent or carrier.


15

4. The use of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, according to claim 1 in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

- 20 5. The use of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, according to claim 1 in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

A B S T R A C TTITLE : QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula I



wherein each of Z^1 , m , R^1 , n , R^3 , Z^2 and R^{14} have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-

proliferative agent in the containment and/or treatment of solid tumour disease.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES.

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.